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Paraneoplastic

neurologic

diseases

(PNDs)

arise

when

systemic

malignancies express proteins normally restricted to neurons. Abnormal
expression of a neuronal protein by tumor cells in the periphery results
in an autoimmune response that then targets both the tumor and the
nervous system. These diseases offer a unique opportunity to gain
insight into the mechanisms behind both tumor immunity and neuronal
autoimmunity.

The Hu syndrome is an example of PND that affects

patients with small cell lung cancer (SCLC).

Hu patients are diagnosed

by the presence of antibodies in the blood that recognize the HuD
antigen. HuD is normally restricted in expression to neurons of both the
peripheral and central nervous systems, but ectopically expressed by
SCLCs.

Despite its expression in virtually all SCLCs, only a small

fraction of SCLC patients go on to develop neurologic disease.

These

patients mount an impressive immune response to their cancer that
results in remarkable tumor immunity to this typically aggressive
malignancy.

Although antibodies to HuD are important diagnostic

criteria for the disease, they are not sufficient for disease pathogenesis.
Because HuD is an intracellular protein, CD8 T cells are more prone to
mediate the destruction of HuD-expressing SCLC cells and neurons.

We

previously demonstrated that patients with paraneoplastic cerebellar
degeneration (PCD), another form of PND, harbor CD8 T cells specific for
the onconeural antigen Cdr-2, suggesting that CD8 T cells mediate
tumor immunity and neuronal degeneration in these patients.

To study

the CD8 T cell response to HuD, we performed an exhaustive screen of
the entire HuD peptide library to identify the immunodominant murine
CD8 T cell epitope of the protein.

We showed that mice are peripherally

tolerized to this neuron-specific protein, which could help to explain why
most

SCLC

patients

expression of HuD.

remain

neurologically

intact

despite

tumor

In addition, HuD-specific CD8 T cells were able to

traffic to the central nervous system in an adoptive transfer model,
however these cells were not sufficient to induce neurologic degeneration.
To translate these results to the clinic, we screened the HuD peptide
library over 8 human MHC I alleles in order to define HLA-restricted
epitopes of the protein. This lead to the discovery of two human CD8 T
cell epitopes of HuD. Using tetramers specific for these HLA-restricted
epitopes, we demonstrated that patients with the Hu syndrome harbor
cytotoxic HuD-specific CD8 T cells in their blood.

By combining our

results from the clinic with the mouse system we are closer to
understanding how the immune system is able to mediate both tumor
immunity and neuronal degeneration in patients with the Hu syndrome.

For Mom and Dad, my most valuable mentors

iii

Acknowledgements

First and foremost, I would like to thank my thesis advisor Bob Darnell,
for his support and enthusiasm. He has let me grow into my own as a
scientist by providing continual encouragement and advice.

I especially

appreciate our trips to the RU Hospital. I have a great deal of admiration
for him as a physician and as a scientist, and I know that his mentorship
will continue to guide me throughout my career.

Many thanks to all the members of the Darnell lab for making the past
five years as fun and exciting as possible.

Most especially, thank you to

Ashby Thomas, Travis Williams, Patricia Foo, Emily Conn, Kevin O’
Donovan, Graeme Couture, Matteo Ruggiu, Jack Fak, Jennifer Darnell,
Mithila Jegathesen, Elvira Lugo, Randy Longman, Brad Rosenberg,
Salina Parveen, Teresa Ramirez-Montegut, Julia Kaufman, Mayu Frank
and Noreen Buckley.

Thank you to Jeff Smith.
without Jeff.

I would not have made it through to the end

He has been a supportive, entertaining, interesting and

funny person to work with every day. He has helped me overcome my
computer challenges, and so much more.
to say thank you, I would use it here.

iv

If there were a stronger way

Thank you to James Okano for his advice over the past few years, and for
providing the HuD knockout mice and recombinant adenoviruses.
Thank you to Nishath Rehman and Gulayse Ince-Dunn for their help
breeding and genotyping the HuD knockout mice.

I owe many thanks to my thesis committee members, Bruce McEwen and
Nina Papavisiliou for their advice and support.

And I am extremely

grateful to Joan Goverman for coming all the way from the west coast to
participate as my outside committee member.

Thanks to Dean Strickland, Kristen Cullen, Marta Delgado, Cristian
Rosario, and Sue Ann Chong for making my time at Rockefeller as easy
and comfortable as possible.

A special thanks to Bianca Santamasso and Nathalie Blachere for their
mentorship. Together, they have taught me most of what I know about
mouse immunology. I owe them so many thanks for their continued
support and sound advice.

Thank you to Wendy Roberts, for her friendship and guidance.

Her

strength and encouragement have helped me make important decisions,
and her wit and personality have made my experience in the lab so much

v

fun.

She has picked me up and dusted me off during my most difficult

times and for that I am very thankful.

I want to thank my family and friends for their love and support.

They

have enthusiastically let me share my work with them and that has
made my experience at Rockefeller so much sweeter.

A special thanks

to Elizabeth, for her advice on all things scientific and otherwise.

Thank

you to Daniel, for his patience, understanding and humor. Having him
in my corner has meant a lot. Finally, and most importantly, a very
special thanks to my mom and dad. They have been my biggest source
of strength and my most enthusiastic supporters from the beginning.

vi

Table of Contents

CHAPTER I. INTRODUCTION…………………………………………………….1
PARANEOPLASTIC NEUROLOGIC DEGENERATIONS……………………….1
Anti Hu syndrome…………………………………………………………………4
TOLERANCE MECHANISMS TO SELF ANTIGENS……………………………8
Central tolerance………………………………………………………………….10
Peripheral tolerance………………………………………………………………11
Regulatory T cells…………………………………………………………………15
IMMUNOSURVEILLANCE AND INFLAMMATION OF THE CENTRAL
NERVOUS SYSTEM…………………………………………………………………19
The blood-brain barrier………………………………………………………….20
Inflammation in the CNS…………………………………………………………21
Experimental autoimmune encephalomyelitis……………………………….23
Immunosuppression in the CNS……………………………………………….24
CD8 T cell mediated disease in the CNS……………………………………..25
Regulatory T cells in the CNS…………………………………………………..28
TOLERANCE TO CENTRAL NERVOUS SYSTEM ANTIGENS……………..31
Tolerance to the myelin proteins……………………………………………….31
Tolerance to neuronal proteins?..........................................................34
SPECIFIC AIMS………………………………………………………………………35
CHAPTER II. MATERIALS AND METHODS…………………………………38

vii

PEPTIDES……………………………………………………………………………..38
Materials and Methods- Mouse……………………………………………………38
MICE……………………………………………………………………………………38
HuD PEPTIDE SCREEN……………………………………………………………38
IMMUNIZATIONS……………………………………………………………………39
PREPARATIONS OF CELLS FROM THE BRAIN………………………………39
PREPARATION OF PRIMARY MURINE KIDNEY CELLS……………………40
ADENOVIRUS PRODUCTION…………………………………………………….40
RETROVIRUS PRODUCTION……………………………………………………..41
ELISPOT ASSAY……………………………………………………………………..41
MURINE DENTRITIC CELL PREPARATION……………………………………42
MOUSE ANTIBODY TITERS………………………………………………………42
WESTERN BLOT WITH CELL LYSATES……………………………………….43
MOUSE CD8 T CELLS STIMULATIONS………………………………………..43
ADOPTIVE TRANSFER……………………………………………………………..44
IN VIVO CTL ASSAY………………………………………………………………..44
FLOW CYTOMETRY…………………………………………………………………46
TETRAMER STAINING……………………………………………………………..46
IN VITRO CTL ASSAY………………………………………………………………46
RMA/S ASSAY……………………………………………………………………….47
Materials and Methods- Human…………………………………………………..48
iTOPIATM SCREEN…………………………………………………………………..48
PERIPHERAL BLOOD ISOLATION………………………………………………49

viii

DENDRITIC CELL CULTURE……………………………………………………..49
CD8 T CELL ISOLATION…………………………………………………………..50
IN VITRO STIMULATION OF HUMAN PERIPHERAL BLOOD T CELLS…50
TETRAMER STAINING ON HUMAN T CELLS…………………………………50
QUANTITATIVE WESTERN BLOT WITH HUMAN SERA……………………51
TETRAMER+ T CELL SORTING………………………………………………….51
CHAPTER III. IDENTIFICATION OF THE IMMUNODOMINANT H-2b
CD8 T CELL EPITOPE OF HUD………………………………………………...53
INTRODUCTION……………………………………………………………………..53
RESULTS……………………………………………………………………………...53
Comprehensive

screen

to

identify

potential

mouse

H-2b

HuD

epitopes…………………………………………………………………………….53
Identification of the immunodominant H-2b HuD epitope………………….54
Pertussis Toxin is required for the generation of IFNγ-secreting HuDspecific CD8 T cells……………………………………………………………..59
Db MHC I molecules present p321…………………………………………….60
Characterization of HuDp321-specific T cells……………………………….61
Cytolytic function of HuDp321-specific T cells in vitro…………………….64
Cytolytic function of HuDp321-specific T cells in vivo……………………..69
SUMMARY…………………………………………………………………………….72
CHAPTER IV. TOLERANCE TO HUD IN THE MOUSE…………………..75
INTRODUCTION……………………………………………………………………..75
RESULTS……………………………………………………………………………...76

ix

HuDp321 specific T cells do not secrete IFNγ ex vivo after adenovirusHuD immunization………………………………………………………………..76
HuDp321 specific T cells expand in vivo after immunization with
HuD………………………………………………………………………………...77
HuAp268-specific T cells are absent from the H-2b repertoire…………..81
HuDp321 specific T cells do not cross-react with HuA……………………83
Mice are tolerized to HuD……………………………………………………….85
HuC-deficient mice remain tolerized to HuD…………………………………87
CD4 depletion does not overcome tolerance to HuD……………………….89
AIRE does not regulate tolerance to HuD…………………………………….91
SUMMARY…………………………………………………………………………….91
CHAPTER V. HUD-SPECIFIC CD8 T CELLS IN THE CNS……………….95
INTRODUCTION……………………………………………………………………..95
RESULTS……………………………………………………………………………...96
Adoptive transfer of HuD CD8 T cells………………………………………...96
HuDp321-specific CD8 T cells can traffic to the central nervous
system.............................................................................................97
HuDp321-specific CD8 T cells from the central nervous are capable of
secreting IFNγ in vitro…………………………………………………………100
HuDp321-specific CD8 T cells in the central nervous system are not
sufficient for the induction of inflammation and neurologic
degeneration…….............................................................................102

x

HuDp321-specific CD8 T cells in the inflamed CNS are not sufficient for
the induction of neuronal degeneration…………………………………….104
SUMMARY………………………………………………………………………….107
CHAPTER VI. IDENTIFICATION OF HUMAN HLA CD8 T CELL
EPITOPES OF HUD………………………………………………………………111
INTRODUCTION……………………………………………………………………111
RESULTS…………………………………………………………………………….112
A comprehensive screen to identify human HuD epitopes……………...112
HuDp157 is a naturally processed A2.1 epitope………………………….113
HuDp157 specific T cells are present in the blood of Hu patients…….117
HuDp157-specific CD8 T cells from patients are functional cytotoxic T
cells……………………………………………………………………………….117
HLA A3.1 restricted HuD-specific CD8 T cells from patients are functional
cytotoxic T cells…………………………………………………………………120
SUMMARY…………………………………………………………………………..124
CHAPTER VII. DISCUSSION…………………………………………………..130
REFERENCES……………………………………………………………………..148

xi

List of Figures

CHAPTER I.
FIGURE 1. MODEL OF ANTI-HU SYNDROME………………………………………….2

CHAPTER III.
FIGURE 1. p321 IS THE IMMUNODOMINANT CD8 T CELL EPITOPE OF
HUD………………………………………………………………………..55-56
FIGURE 2. PERTUSSIS TOXIN IS REQUIRED FOR HUD-SPECIFIC CD8 T CELL
PRIMING…………………………………………………………………….…58
FIGURE 3. HUDp321 IS PRESENTED ON Db MHC I………………………………..62
FIGURE 4. HUDp321-SPECIFIC CD8 T CELL ARE HIGH AFFINITY T
CELLS………………………………………………………………………….63
FIGURE 5. STIMULATED HUD SPECIFIC CD8 T CELLS DISPLAY A
CHARACTERISTIC CELL SURFACE PHENOTYPE…………………..65
FIGURE 6. HUDp321 SPECIFIC CD8 T CELLS CAN KILL IN VITRO……………67
FIGURE 7. FREQUENCY OF IN VITRO STIMULATED CD8 T CELLS……………68
FIGURE 8. DC PULSED WITH COGNATE PEPTIDE ENHANCE KILLING BY
HUDp321 SPECIFIC CD8 T CELLS IN VIVO………………………….71
FIGURE 9. HUDp321 SPECIFIC CD8 T CELLS CAN KILL IN VIVO………………73

CHAPTER IV.
FIGURE 1. HUDp321 SPECIFIC CD8 T CELLS DO NOT SECRETE IFNg
DIRECTLY EX VIVO AFTER ADV HUD IMMUNIZATION……………78
FIGURE 2. HUDp321 SPECIFIC CD8 T CELL EXPAND IN VIVO AFTER
ADENOVIRUS HUD IMMUNIZATION……………………………………80
FIGURE 3. HUAp268 BINDS WITH HIGH AFFINITY TO Db MHC I……………….82

xii

FIGURE 4. HUAp268 SPECIFIC CD8 T CELLS ARE ABSENT FROM THE H-2b
REPERTOIRE…………………………………………………………………84
FIGURE 5. C57BL/6 MICE ARE TOLERIZED TO HUD……………………………..86
FIGURE 6. HUC-/- MICE REMAIN TOLERIZED TO HUD………………………….88
FIGURE 7. CD4 DEPLETION DOES NOT OVERCOME TOLERANCE TO
HUD…………………………………………………………………………….90
FIGURE 8. AIRE DOES NOT REGULATE TOLERANCE TO HUD…………………92

CHAPTER V.
FIGURE 1. ADOPTIVE TRANSFER OF HUDp321 SPECIFIC CD8 T CELLS……98
FIGURE 2. TRANSFERRED CD8 T CELLS TRAFFIC TO THE CNS………………99
FIGURE 3. TRANSFERRED CD8 T CELLS IN THE CNS ARE NOT
ANERGIC…………………………………………………………………..…101
FIGURE 4. PERIPHERAL APC ARE RECRUITED TO THE CNS IN EAE……….103
FIGURE 5. PERIPHERAL APC ARE NOT RECRUITED TO THE CNS AFTER
ADOPTIVE TRANSFER OF HUD SPECIFIC CD8 T CELLS………..105
FIGURE 6. ADOPTIVE TRANSFER OF HUDp321 SPECIFIC CD8 T CELLS INTO
EAE MICE…………………………………………………………………….106
FIGURE 7. ADOPTIVE TRANSFER OF HUDp321 SPECIFIC CD8 T CELLS INTO
EAE MICE DOES NOT RESULT IN NEURONAL
DEGENERATION…………………………………………………………..108
FIGURE 8. MHC I AND II ARE UPREGULATED IN THE CNS DURING EAE…109

CHAPTER VI.
FIGURE 1. SCREENING HLA A2.1 RESTRICTED PEPTIDES IN AAD
MICE…………………………………………………………………………114

xiii

FIGURE 2. HUDp157 IS A NATURALLY PROCESSED A2.1-RESTRICTED
EPITOPE…………………………………………………………………….116
FIGURE 3. HUDp157-SPECIFIC T CELLS ARE PRESENT IN HU PATIENT
BLOOD…………………………………………………………………118-119
FIGURE 4. HUDp157-SPECIFIC T CELLS FROM PATIENTS ARE FUNCTIONAL
CYTOTOXIC T CELLS………………………………………………122-123
FIGURE 5. HUDp133 IS AN HLA A3.1 RESTRICTED EPITOPE OF
HUD…………………………………………………………………….125-126
FIGURE 6. HUDp133-SPECIFIC T CELLS ARE FUNCTIONAL CYTOTOXIC T
CELLS…………………………………………………………………..127-128

CHAPTER VII.
FIGURE 1. REVISED MODEL OF ANTI-HU SYNDROME…………………………131

xiv

CHAPTER I. INTRODUCTION

Paraneoplastic neurologic degenerations (PNDs)
Paraneoplastic

neurologic

degenerations

(PNDs)

offer

a

unique

opportunity to gain insight into the mechanisms behind tumor immunity
and neuronal autoimmunity.

These diseases arise when systemic

malignancies express proteins normally restricted to neurons. Abnormal
expression of a neuronal protein by tumor cells in the periphery results
in an autoimmune response that then targets both the tumor and the
nervous system.

PNDs are arguably the most well documented

examples of naturally occurring tumor immunity, most commonly
associated with breast, ovarian and lung tumors. The tumor immunity
generated is so effective that PND patients often present first with
neurologic symptoms before their cancer is diagnosed. It is important to
note that the majority of cancer patients never mount a detectable
immune response to their tumor, but in this small subset of PND
patients (0.01%) the immune system responds to the cancer, resulting in
both remarkable tumor immunity as well as autoimmune neurologic
degeneration (Fig 1).

The immune response to neuronal proteins ectopically expressed by
tumor cells in PND patients serves to connect their tumor immunity and
neuronal degeneration. Evidence for an immune-mediated disease came
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Fig 1. Model of anti-Hu syndrome. The presence of a small cell lung
cancer tumor in the periphery that expresses HuD results in an immune
response to the HuD protein that is able to respond to the tumor,
resulting in tumor immunity, and traffic to the nervous system to target
HuD-expressing neurons, resulting in neuronal degeneration.
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from the identification of high titer antibodies in the blood and
cerebrospinal fluid of PND patients (Graus, Elkon et al. 1986; Furneaux,
Reich et al. 1990). Patient antibodies were used to identify so-called
onconeural proteins aberrantly expressed by tumors and naturally found
in the nervous system.

Although the presence of high titer autoantibodies in PND patients serves
as a diagnostic tool, their role in disease pathogenesis remains unclear.
Onconeural antigens are intracellular proteins and therefore not easily
accessible to circulating antibodies.

Furthermore, attempts to establish

animal models of disease based on the generation of high titer antibodies
to onconeural antigens have failed (Sakai, Gofuku et al. 1995; Sillevis
Smitt, Manley et al. 1995).

Given the intracellular nature of the PND

antigens, it seems likely that T cells play an important role in disease
pathogenesis.

This is evidenced by the presence of lymphocytic

infiltrates into relevant regions of the CNS in PND brains obtained at
autopsy (Jean, Dalmau et al. 1994; Verschuuren, Chuang et al. 1996).
Clear evidence for T cell involvement in disease pathogenesis has been
demonstrated

for

paraneoplastic cerebellar

degeneration

(PCD), a

particular type of PND that affects women with breast and ovarian
cancer.

Patients with PCD have high titer antibody to Cdr2, an

intracellular protein normally expressed exclusively by Purkinje cells in
the cerebellum.

Freshly isolated CD8 T cells from the blood of PCD

3

patients have been shown to kill Cdr2-expressing targets in a cytotoxic T
lymphocyte (CTL) assay, and activated T cells are found in the
cerebrospinal fluid of PCD patients (Albert, Darnell et al. 1998; Albert,
Austin et al. 2000).

Taken together, this evidence suggests that T cells

play a critical role in the pathogenesis of PCD.

Anti-Hu Syndrome
Like PCD, anti-Hu syndrome (also referred to as subacute sensory
neuropathy/encephalomyelitis) is a particular form of PND characterized
by neuronal loss and inflammatory infiltrates of the nervous system
(Henson, Hoffman et al. 1965; Horwich, Cho et al. 1977; Anderson,
Cunningham et al. 1987).

Patients with anti-Hu syndrome develop

neurologic symptoms that affect discrete areas of the nervous system
including the dorsal root ganglia, limbic system, cerebellum, brainstem,
motor or autonomic nervous system.

Most patients go on to develop

multifocal neuronal degeneration and die from neuronal causes, on
average, seven months after diagnosis (Dalmau, Graus et al. 1992).
Antisera from patients recognize the Hu antigen, which is normally
restricted to neurons of both the peripheral and central nervous systems.
Anti-Hu syndrome is associated with Small Cell Lung Cancer (SCLC) and
patients are able to generate impressive tumor immunity to this typically
aggressive malignancy. SCLCs from anti-Hu patients are usually limited
to single nodules, which are discovered only after presentation of
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neurologic symptoms (Dalmau, Graus et al. 1992).

Although very few

SCLC patients go on to develop PND (0.01%), all SCLCs express the Hu
antigen (Manley, Smitt et al. 1995). The presence of high titer antibody
to Hu allows for diagnosis of anti-Hu syndrome and is correlated with
natural tumor immunity. Apart from the small cohort of SCLC patients
with the Hu syndrome, 15% of SCLC tumors generate a low titer anti-Hu
antibody response in the absence of neurologic disease (Dalmau,
Furneaux et al. 1990).

Patients with low titer antibodies have limited

stage tumors and better prognoses compared to SCLC patients with no
detectable Hu antibodies (Dalmau, Furneaux et al. 1991; Graus, Dalmou
et

al.

1997).

Uncovering

the

differences

between

high

titer,

neurologically affected PND patients and low titer, neurologically normal
SCLC patients will undoubtedly improve our understanding of the
mechanisms behind both tumor immunity and neuronal autoimmunity.

The Hu antigen recognized by patient antisera is part of a protein family
consisting of four members: HuA, HuB, HuC, and HuD.

Hu family

members are highly homologous to a Drosophila nuclear protein ELAV.
Deletion mutants of elav are embryonic lethal due to abnormal neuronal
development (Robinow, Campos et al. 1988; Robinow and White 1991).
The sequence of Hu genes is highly conserved between individual Hu
family members within and across species (Okano and Darnell 1997).
The Hu proteins bind to RNA, and are found in the nuclei of neurons of
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both the peripheral and central nervous systems (Ma, Cheng et al. 1996;
Keene 1999). HuA is the ancestral Hu gene, and unlike HuB, HuC, and
HuD, is ubiquitously expressed throughout the body (Ma, Cheng et al.
1996; Okano and Darnell 1997). HuB, HuC, and HuD are restricted to
neurons, and all neurons contain one or more of the Hu proteins; for
example, the dorsal root ganglia contain all three Hu proteins whereas
Purkinje cells in the cerebellum contain HuC exclusively (Okano and
Darnell 1997).

Antisera from patients with the Hu syndrome react with

HuB, HuC, and HuD however only HuD is expressed by SCLCs (Manley,
Smitt et al. 1995).

HuD, then, appears to be the antigen responsible for

initiating an autoimmune response to SCLC in the periphery. This HuDspecific immune response is then able to traffic to the nervous system
and target neurons expressing the Hu antigen.

Patients with the Hu

syndrome present first with neurologic disease affecting one region of the
nervous system but go on to develop multifocal neurologic degeneration.
If the initial autoimmune attack is directed against HuD specifically, it
may spread to other Hu family members and target neurons expressing
various combinations of the Hu proteins.

There is no difference between the HuD gene expressed by SCLCs and by
neurons (Carpentier, Voltz et al. 1998).
tumors found in PND patients are

Histologic characteristics of
no different from those in

neurologically normal SCLC patients except that they may be heavily
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infiltrated with inflammatory cells (Rosenblum 1993).

Thus, the

initiation of an autoimmune response to HuD does not rely on some
deviation in the protein or tumor in anti-Hu patients.
patients with the Hu syndrome

Importantly,

do not succumb to peripheral

autoimmunity and tissues outside of the nervous system are never
attacked. If the ultimate autoimmune response is able to recognize other
Hu family members in addition to HuD, it should not recognize HuA, as
this would lead to massive peripheral autoimmunity given HuA’s
ubiquitous expression pattern.

The autoimmune response to Hu is evidenced by the presence of
autoantibodies in the blood and cerebrospinal fluid of anti-Hu patients,
however given that the Hu proteins are sequestered within the nuclei of
neurons, it seems unlikely that antibodies play a dominant role in
disease pathogenesis. Rather, T cells specific for HuD are more apt to
generate anti-tumor immunity and neuronal degeneration. Cell mediated
autoimmunity is suggested by the presence of activated T cell in the
cerebrospinal fluid of anti-Hu patients.

Moreover, the immune

response in patients is Th1-skewed, with Th1 CD4 helper T cells and
IgG1 antibodies present in circulation (Jean, Dalmau et al. 1994;
Benyahia, Liblau et al. 1999).

Attempts to create mouse models of the

disease by immunizing with whole HuD protein fail to induce neuronal
autoimmunity despite the generation of high titer antibodies to Hu
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(Sillevis Smitt, Manley et al. 1995).

For these reasons, T cells appear to

play an essential role in the Hu syndrome, and understanding the
mechanisms behind tumor immunity and neuronal autoimmunity
should focus on the T cell response to the Hu antigen.

Anti-Hu syndrome is an aggressive illness.
because

disease

involves

irreversible

Prognosis is usually poor

neuronal

subacutely so that intervention is delayed.

loss

and

evolves

When the syndrome is

diagnosed, treatment of this presumably T cell mediated PND relies on
an immunosuppressant like tacrolimus and elimination of the underlying
SCLC tumor (Albert, Austin et al. 2000).

To date, there is no known

immunogenic epitope of the HuD protein, which severely limits our
ability to examine T cell responses to HuD in patients with the Hu
syndrome. In order to more effectively diagnose and treat patients with
this aggressive autoimmune disease, we must identify immunogenic
epitopes of HuD so that we can isolate and study T cells specific for this
antigen.

Tolerance mechanisms to self-antigens
HuD is a self-protein naturally expressed by neurons.

To understand

how the body generates autoimmunity against HuD, it is important to
understand

the

mechanisms

responsible

for

tolerance

induction.

Tolerance is the body’s defense against reactivity to self. Lack or loss of
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tolerance leads to immune responses against self-proteins, eventually
resulting

in

maintenance

clinical
of

autoimmune

tolerance

involves

disease.

The

interactions

induction

between

presenting cells (APC) and lymphocytes (Pugliese 2004).

and

antigen
Central

tolerance happens in the thymus and is responsible for purging the T cell
repertoire of self-reactive clones (Gallegos and Bevan 2004) (Starr,
Jameson et al. 2003).

Ideally, any lymphocyte capable of recognizing

self-peptide is eliminated during development, sculpting an immune
system that is armed with T cells specific only for foreign antigens.

The

thymic architecture is designed to ensure that mature T cells emerge
from the thymus with the ability to recognize self-MHC molecules but not
self-peptides. Cortical thymic epithelial cells (cTECs) are responsible for
positive selection of lymphocytes whereas medullary thymic epithelial
cells (mTECs) delete autoreactive cells.

This process is imperfect,

however, and self-reactive clones escape into the periphery where there is
potential recognition of self-tissue (Gallegos and Bevan 2006) (Bouneaud,
Kourilsky et al. 2000).
avoid

autoimmune

In order to silence these self-specific T cells and

disease,

peripheral

tolerance

exists.

The

mechanisms responsible for peripheral tolerance are varied and can act
directly on T cells, through their deletion or inactivation, or through
accessory cells, namely regulatory T cells.

9

Central tolerance
The role of central tolerance in preventing autoimmunity was highlighted
by the discovery of AIRE, a transcription factor expressed in the thymus
that controls the ectopic expression of tissue-specific antigens by mTECs
(Holmdahl 2007).

Thymic stromal cells do not endogenously express

proteins normally restricted in expression to particular organs.

AIRE,

and perhaps other undiscovered transcription factors are responsible for
driving expression of these tissue-specific antigens in the thymus for
deletion of autoreactive T cell clones.

AIRE was first identified as the

underlying gene responsible for the human autoimmune disorder termed
APECED (Peterson, Nagamine et al. 1998).
autoimmune

polyendocrinopathy

Patients with APECED (for

candidiasis ectodermal

dystrophy)

develop multiorgan autoimmune disease due to a lack of functional AIRE
protein. As in humans, loss of AIRE in mice leads to the development of
multiorgan autoimmune disease that is dependent on the absence of
AIRE from thymic stromal cells (Liston, Lesage et al. 2003) (Anderson,
Venanzi et al. 2002).

The ectopic expression of tissue-restricted

antigens by AIRE in the thymus is necessary for the deletion of selfspecific T cell clones and protection against autoimmune disease.
Recently, it was suggested that the role of AIRE in preventing
autoimmunity be extended to include deletion of autoreactive T cells in
the periphery. AIRE was shown to be expressed in lymph node stromal
cells in a transgenic mouse model of tolerance induction.
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Ectopic

expression of tissue-restricted antigens in the lymph nodes resulted in
elimination of self-reactive T cell clones (Lee, Epardaud et al. 2007). In
this model, a cytosolic form of ovalbumin (OVA) under the control of a
tissue-specific promoter was endogenously processed and presented onto
MHC I molecules by a stromal cell population in the lymph node cortex.
Endogenous presentation of OVA in the lymph node was an effective
means of inducing tolerance in naïve transgenic OVA-specific CD8 T
cells.

Peripheral tolerance
Peripheral tolerance is designed to suppress the activity of self-specific T
cell that have escaped thymic deletion. The mechanisms responsible for
peripheral tolerance can be distinguished between those that act on
responding T cells directly and those that rely on additional cell types,
namely regulatory T cells.

T-cell intrinsic mechanisms include

ignorance, anergy, and activation-induced cell death (Walker and Abbas
2002). Ignorance is achieved by sequestering tissue-specific antigens in
areas not easily accessed by lymphocytes (Alferink, Tafuri et al. 1998).
Limiting the amount of antigen in the periphery is also an important
means of maintaining T cell ignorance, since there is a threshold below
which T cells are unable to respond (Kurts, Miller et al. 1998).

Anergy

is the functional inactivation of a T cell upon encounter with antigen.
Inhibitory receptors, most notably CTLA-4 and PD-1, are responsible for
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inducing anergy in response to T cell receptor (TCR) ligation. CTLA-4 on
the surface of T cells binds to the co-stimulatory molecules B7-1 and B72, and was shown to be critical for anergy induction in vivo (Perez, Van
Parijs et al. 1997). PD-1 is highly expressed on the surface of anergic T
cells, and mice lacking this receptor develop autoimmune disorders
(Nishimura, Nose et al. 1999). Activation-induced cell death and anergy
depend on T cell recognition of MHC-peptide complexes on APCs so that
APCs, particularly dendritic cells, play an important role in maintaining
tolerance in the periphery.

Activation-induced cell death is arguably

the most effective means of preventing autoimmunity since it results in
the elimination of self-specific T cell clones from the repertoire.
Because self-antigens naturally persist instead of being cleared from the
body, autoreactive T cells that repetitively engage their TCR may be
subject to apoptosis via activation-induced cell death.

Ligation of the

Fas death receptor is critical to this pathway, and defects in Fas
signaling are associated with human autoimmune lymphoproliferative
syndrome (ALPS) (Fisher, Rosenberg et al. 1995).

Experimental evidence has shown that bone marrow derived APCs and
not the peripheral tissue itself are responsible for inducing peripheral
tolerance (Kurts, Heath et al. 1996; Kurts, Kosaka et al. 1997).
Recognition of MHC-peptide complexes on APCs by T cells specific for
tissue-restricted antigens results in tolerization, either though deletion or
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anergy (Heath, Kurts et al. 1998) (Redmond and Sherman 2005). Using
a transgenic model of peripheral tolerance induction in which OVA is
expressed in the pancreas and kidney, it was shown that naïve
transgenic OVA-specific CD8 T cells undergo tolerance in the form of
deletion as a result of OVA presentation in the periphery. Deletion was
preceded by an initial period of activation and proliferation that did not
translate into effective priming (Kurts, Kosaka et al. 1997).

Like CD8 T

cells, CD4 T cells are tolerized in the periphery by APCs that have
acquired exogenous antigen (Heath, Kurts et al. 1998).

In transgenic

mice that express hemagglutinin (HA) in various parenchymal cells, HAspecific CD4 T cells are anergized by presentation of HA on bone marrow
derived APCs (Adler, Marsh et al. 1998).

Bone marrow derived APCs

play a pivotal role in maintaining tolerance in the periphery to both CD4
and CD8 T cell epitopes.

Experimental evidence indicates that myeloid

DCs in particular are responsible for tolerance induction (Albert,
Jegathesan et al. 2001).

DCs are exceptionally adept at antigen

processing and presentation, with the capacity to take up antigens and
present them to T cells as peptides bound to MHC I and II molecules
(Mellman and Steinman 2001).

Compared to other antigen presenting

cells, DCs are more effective at stimulating naïve T cells and shaping the
quality of immune responses.

The types of antigens captured and

presented by DCs include both foreign and self-proteins.

Activation of T

cells to foreign antigens is required for effective clearance of invading
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pathogens. Conversely, suppression of T cells specific for self-antigens is
necessary for the prevention of autoimmunity. DCs do not endogenously
express tissue-specific proteins and must therefore capture peripheral
tissue for processing and presentation of self-peptides onto MHC I and
MHC II molecules.

To this end, DCs utilize a pathway termed cross

presentation that allows exogenous antigen to be presented on MHC I as
well as MHC II molecules to CD8 and CD4 T cells, respectively (Mellman
and Steinman 2001).

The factors that determine whether DC epitope

presentation will result in priming or tolerization are still unclear.

For

CD8 T cell priming via cross-presentation by a DC, it was shown that
cognate CD4 T cells are required for the generation of a productive
immune response (Albert, Jegathesan et al. 2001).

The absence of

cognate CD4 T cell help resulted in tolerance of CD8 T cells.

A

coordinated response by CD8 and CD4 T cells is therefore necessary for
the initiation of an effective immune response, and activation of cognate
CD4 T cells is an important checkpoint for CD8 T cell priming.

The maintenance of peripheral tolerance depends on a persistent source
of antigen. Both transgenic and non-transgenic systems have been used
to study the mechanisms behind peripheral tolerance induction.

The

non-transgenic model of peripheral tolerance to the murine ovarianspecific antigen ZP3 highlights the requirement for a constant source of
antigen in the periphery (Garza, Agersborg et al. 2000).
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Females are

naturally tolerized to ZP3, requiring 100-fold more antigen to elicit an
immune response compared to males. Tolerance in females was shown
to depend on the presence of endogenous ZP3, as removal of the ovaries
from neonates converted the female immune response into that of males.
Moreover, exposure to neonatal antigen was insufficient for the
maintenance of tolerance, which required a constant source of antigen
throughout adulthood.

When the ovaries were removed from adult

females that then received syngeneic ovarian implants followed by
immunization to ZP3, the mice developed overt ovarian autoimmune
disease. Normal females given ovarian implants and immunized to ZP3
maintained tolerance to the antigen and did not exhibit autoimmunity.

Regulatory T cells
Regulatory T cells are a specialized population of cells critical to the
maintenance of peripheral tolerance.

Peripheral tolerance induction by

regulatory T cells is achieved by active suppression of effector T cells.
Most regulatory T cells are classified as CD4+CD25+ cells that express the
transcription factor FoxP3, and in both humans and mice represent less
than 10% of the total CD4 T cell population (Akbar, Vukmanovic-Stejic et
al. 2007).

There are two distinct classes of regulatory T cells,

distinguished by their developmental course. Natural regulatory T cells
emerge from the thymus as FoxP3+ cells with the intrinsic ability to
inhibit the proliferation of activated T cells, whereas induced or adaptive
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regulatory T cells are converted from activated effector or memory CD4 T
cells in the periphery (Itoh, Takahashi et al. 1999; Akbar, VukmanovicStejic et al. 2007). Production of natural regulatory T cells occurs
through presentation of self-peptides in the thymus.

The precise signals

leading to the generation of natural regulatory T cells, as opposed to the
deletion of self-specific thymocytes, are not well understood (Picca and
Caton 2005) (Apostolou, Sarukhan et al. 2002).

Both pathways require

recognition of self-peptide in the thymus by developing lymphocytes,
however the type of APC responsible for antigen presentation, as well as
the strength of the TCR-MHC interaction, may help to determine the fate
of self-reactive T cells.

A peripheral source of self-antigen is required for the maintenance of
effective regulatory T cells from thymic emigrant precursors (Picca and
Caton 2005). Natural regulatory T cells emerge from the thymus with an
intrinsic ability to suppress effector T cells, however their survival
depends on continual exposure to antigen in the periphery.

This has

been demonstrated in a non-transgenic model of autoimmune thyroiditis
(Seddon and Mason 1999). Autoimmune thyroiditis results in high titer
antibodies against thyroglobulin and extensive leukocytic infiltration of
the thyroid glands.

Development of disease can be prevented by

reconstitution with natural regulatory T cells.

In order to study the

dependency of these regulatory T cells on peripheral antigen, the thyroid
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was ablated in utero before the emergence of T cells from the thymus so
that no peripheral source of antigen existed. Peripheral CD4 T cells or
thymocytes from athyroid animals were transferred into thyroiditis-prone
hosts. Whereas thymocytes from athyroid animals were able to function
effectively as regulatory T cells and prevent thyroiditis, peripheral CD4 T
cells from athyroid animals were ineffective suppressors and could not
inhibit the development of autoimmunity. Peripheral CD4 T cells were
presumably ineffective due to their lack of exposure to antigen in the
periphery in athyroid animals.

In addition, the ineffectiveness of

peripheral CD4 T cells proved to be antigen-specific, as these cells were
able to prevent the development of other forms of autoimmunity such as
diabetes.

There are various pathways that lead to the production of regulatory T
cells in the periphery from effector or memory CD4 T cells. Tr1 cells are
a type of adaptive regulatory T cell, defined by their dependence on IL-10
(Roncarolo, Gregori et al. 2006).

IL-10 is required for the induction of

Tr1 cells in vivo, and is responsible, in part, for Tr1-mediated
suppression. Suppression by Tr1 cells is carried out by secretion of the
anti-inflammatory cytokines IL-10 and TGF-β.

IL-10 was initially

discovered by its ability to block cytokine secretion from Th1 cells
(Moore, Vieira et al. 1990). Its immunosuppressive properties have been
extended to include down regulation of costimulatory molecules and
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inhibition of pro-inflammatory cytokine production by APCs (Roncarolo,
Gregori

et

al.

2006).

TGF-β

acts

to

inhibit

proliferation

and

differentiation of both CD4 and CD8 T cells (Li, Wan et al. 2006).
Adaptive regulatory T cells, in addition to natural regulatory T cells, have
been shown to play a role in preventing autoimmunity.

Defects in Tr1

cells have recently been discovered in patients with multiple sclerosis
(MS) (Astier, Meiffren et al. 2006).

MS is an autoimmune disease

characterized by inflammation in the CNS and destruction of myelin. Tr1
cells from MS patients were hyporesponsive to stimulation in vitro and
secreted lower levels of IL-10 compared to Tr1 cells from healthy donors
(Astier, Meiffren et al. 2006).

The immune system is responsible for protecting the body from foreign
invaders. It is therefore essential that the immune repertoire be armed
with receptors capable of identifying any foreign substance or organism.
To ensure a sufficient amount of diversity among lymphocytes, the
immune system randomly arranges receptors to create a repertoire that
consists of billions of different clones.

Given the randomness and

magnitude of lymphocyte diversity, a portion of the immune system will
unavoidably be able to recognize self-tissue.

Tolerance is therefore

essential to protect the body from its own defenses.

Maintaining

immunologic tolerance is tantamount to generating effective immune
responses against foreign pathogens.
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The multiple, and sometimes

redundant

mechanisms

behind

tolerance

importance of preventing self-reactivity.

induction

reflect

the

Anti-Hu syndrome offers a

unique opportunity to study tolerance to a self-protein expressed
exclusively in neurons. The fact that all SCLCs express the HuD protein,
but only 15% of SCLC patients mount a detectable immune response to
HuD, suggests that the immune system is normally tolerized to HuD,
and that tolerance is broken in patients with anti-Hu antibodies.

Of the

15% of patients with anti-Hu antibodies, a very small population goes on
to develop neuronal autoimmunity.

This implies an additional

requirement besides the loss of tolerance to HuD for the generation of
brain disease.

The uniqueness of the central nervous system, and the

properties that distinguish it from other tissues in the body, undoubtedly
contribute to the rare incidences of autoimmune mediated neuronal
degeneration.

Immunosurveillance and inflammation of the central nervous
system
The CNS has historically been considered an immune privileged site.
Immune privilege signifies the inability of the immune system to access
and survey certain anatomical sites.

Surveillance of the CNS was

considered impractical due to a lack of lymphatic drainage from the CNS
parenchyma, the absence of traditional antigen presenting cells (APCs),
and the presence of the blood-brain barrier (Ransohoff, Kivisakk et al.
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2003). These factors represented physical and functional barriers that
combined to make the CNS unreachable by the immune system.

We

now understand that the immune system is not excluded from the CNS,
although access is more carefully monitored relative to other tissues.

The blood-brain barrier
The CNS consists of the brain and spinal cord, covered by three layers of
membrane and encased in bone.

Cerebrospinal fluid (CSF) is generated

locally by specialized secretory cells of the choroids plexuses, which are
located within individual ventricles, or cavities, of the brain.

After

formation in the ventricles, CSF circulates through the brain and spinal
cord before being reabsorbed into venous blood.

Recent studies indicate

that CSF also drains into cervical lymph nodes, making it a unique form
of lymph specific to the CNS (de Vos, van Meurs et al. 2002; Karman,
Ling et al. 2004).

The extracellular fluid that bathes the parenchyma of

the brain has access to CSF so that soluble proteins from CNS grey and
white matter can readily reach lymphoid tissues (Ransohoff, Kivisakk et
al. 2003).

Evidence of CSF flow into cervical lymphatics makes it clear

that there is appreciable immune surveillance of soluble CNS antigens.

Movement of cells into the CNS is a tightly regulated process. Capillaries
of the CNS vasculature protect the parenchyma by excluding circulating
cells and macromolecules on account of endothelial tight junctions.
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Tight junctions seal the gap between the blood and CNS, preventing
movement of lymphocytes across the endothelium. Movement of solutes
is also precluded by the inability of endothelial cells to pinocytose.
Together, these unique features of the endothelium are referred to as the
blood-brain barrier.
effective

In a healthy state, the blood-brain barrier is an

impediment

endothelium.

to

However,

lymphocyte

migration

experimental

across

evidence

the

CNS

indicates

that

lymphocytes are able to gain access to the CNS under inflammatory
conditions (Hickey 2001).

TNFα is a proinflammatory cytokine that

causes marked changes in the blood-brain barrier when produced either
locally or systemically (Hickey 2001). In both in vitro and in vivo models,
TNFα has been shown to increase the permeability of the blood-brain
barrier, thereby enhancing the passage of material between the blood
and CNS (Mark and Miller 1999) (Dickstein, Moldofsky et al. 2000).
Other proinflammatory substances such as LPS and IFNγ influence the
permeability of the blood-brain barrier by activating endothelial cells of
the CNS vasculature, resulting in upregulation of adhesion molecule
expression (Hickey 2001).

Inflammation in the CNS
Although the CNS is normally protected from the development of harmful
immune responses, inflammatory reactions can occur behind the bloodbrain barrier. Whereas naïve lymphocytes are rarely found in the
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parenchyma of the brain, activated T cells readily traverse the CNS
regardless of antigen specificity (Karpus and Ransohoff 1998; Becher,
Bechmann et al. 2006).

Antigen specificity becomes important for

retention of T cells behind the blood-brain barrier and the subsequent
initiation of an inflammatory immune response.

Inflammation requires

antigen-specific stimulation of activated T cells that have crossed into the
brain, which in turns depends on the presence of an antigen presenting
cell (APC) in the CNS (Becher, Bechmann et al. 2006) (Perry 2004).
Antigen-specific stimulation of T cells in the CNS is a complicated
process given the multiplicity of APCs with the potential to function as T
cell stimulators.

There are both endogenous and peripheral APCs

present in the inflamed CNS.

Peripheral macrophages and DCs are

recruited as part of the inflammatory response whereas microglia are
resident APCs with the capacity to express MHC and costimulatory
molecules.

In a normal, nonpathologic state, microglia express

insufficient levels of MHC molecules and are therefore incapable of
functioning as APCs (Aloisi 2001).

MHC expression is quickly

upregulated under inflammatory or neurodegenerative conditions so that
microglia become important participants in the CNS immune response
(Aloisi 2001; Carson, Doose et al. 2006).

Despite their role in the

development of CNS inflammation, microglia do not appear to be the cell
type responsible for initiating T cell responses behind the blood-brain
barrier. Rather, peripheral DCs are sufficient for the induction of CNS
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inflammation (Carson, Doose et al. 2006) (Lauterbach, Zuniga et al.
2006) (Greter, Heppner et al. 2005).

The prevailing model for the

generation

with

of

CNS

pathology

begins

the

induction

of

an

inflammatory response as a result of CNS antigen-specific T cell
stimulation by peripheral DCs behind the blood-brain barrier, followed
by infiltration of mononuclear cells and additional T cells into the CNS
parenchyma where microglia are able to direct T cell effector function
(Ransohoff, Kivisakk et al. 2003; Carson, Doose et al. 2006).

Experimental autoimmune encephalomyelitis
The

most

commonly

studied

example

of

CNS

inflammation

is

experimentally induced autoimmune encephalomyelitis (EAE). EAE is a
mouse model of multiple sclerosis (MS) characterized by autoimmunity
directed against components of the myelin sheath. Disease is commonly
mediated by myelin-specific CD4 T cells that have infiltrated the CNS
(Becher, Bechmann et al. 2006).

To generate EAE, mice are immunized

with myelin peptides or proteins (most commonly MOG, PLP or MBP) in
order to prime myelin-specific CD4 T cells in the periphery.

The

pathology is initiated when activated myelin-specific T cells traffic to the
CNS

and

induce

inflammation,

characterized

by

peripheral

APC

recruitment to the brain and spinal cord, upregulation of MHC and
costimulatory

molecules

on

resident

microglia,

demyelination (Becher, Bechmann et al. 2006).
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and

eventual

Peripheral APCs that

have been recruited to the CNS are necessary and sufficient to stimulate
activated myelin-specific CD4 T cells behind the blood-brain barrier
(Greter, Heppner et al. 2005).

Although microglia do not seem to play a

role in the initiation of CNS inflammation, they participate in the ongoing
inflammatory reaction by modifying T-cell effector function within the
parenchyma (Carson, Doose et al. 2006). Using irradiation bone marrow
chimeras, it was shown that expression of CD40 on microglia is
necessary for the exacerbation of EAE (Becher, Durell et al. 2001).
Microglia are capable of phagocytosing antigen when activated under
inflammatory conditions, and experimental evidence suggests that
processing and presentation of myelin epitopes to infiltrating T cells by
resident microglia is important for the progression of CNS disease
(Prineas, Kwon et al. 2001) (Carson 2002).

Immunosuppression in the CNS
Inflammatory responses in the CNS can cause irreparable damage, as
evidenced by autoimmune diseases like EAE and PND.

In order to

prevent immune-mediate neurodegeneration, the CNS has designed ways
to

mitigate

immune

responses

behind

the

blood-brain

barrier.

Regulation of infiltrating lymphocytes by resident brain cells is an active
process designed to limit or suppress CNS inflammation.

Constitutive

expression of FasL in the CNS promotes apoptosis of activated T cells,
and immunosuppressive cytokines, most notably TGF-β, act to inhibit
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inflammation (Bechmann, Mor et al. 1999; Vitkovic, Maeda et al. 2001).
Microglia have the capacity to promote inflammation and tissue damage
in some circumstances, but also function to preserve homeostasis in the
CNS (Minghetti and Levi 1998; Streit 2002).

Neuroprotection is

demonstrated by the role of microglia in the regeneration of motor
neuron axons after facial nerve axotomy (Streit 2002).

Facial nerve

axotomy involves transecting or severing the axons of the facial nerve,
and is a widely used model of degeneration and regeneration of the
nervous system in vivo (Moran and Graeber 2004).

There is effective

communication between neurons and microglia, as evidenced by the
activation of microglia within the CNS subsequent to transection of
axons in the periphery (Streit 2002) (Bessis, Bechade et al. 2007).
Activated, phagocytic microglia surround dying neurons and neuronal
debris, and following axotomy, function to remove synaptic terminals
from the cell body, a process that has been termed “synaptic stripping”
(Moran and Graeber 2004) (Raivich, Jones et al. 1998).

The activation,

proliferation and ensheathment of neurons by microglia in response to
neuronal injury are vital to the regeneration of motor axons, and
highlight the role of microglia as neuroprotective cells in the CNS.

CD8 T cell mediated disease in the CNS
The apparent interactions between microglia and neurons reflect a
dynamic CNS environment that promotes communication amongst
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resident cells.

For antigen-specific T cell mediated neurodegeneration,

there is a requirement for contact between neurons and infiltrating T
cells. In our model of anti-Hu syndrome, disease pathogenesis depends
on the targeting of HuD expressing neurons by activated HuD-specific
CD8 T cells. This in turn requires MHC I expression on neurons, which
then serve as targets for CD8 T cells. Whereas peripheral tissues readily
express MHC I molecules in order to guard against intracellular infection,
healthy neurons have undetectable surface expression of MHC I,
supporting the perception of the CNS as an immune privileged site.
Under pathologic conditions, however, when the CNS environment
switches from being immunosuppressive to inflammatory, neurons
upregulate MHC I expression.

Upregulation of MHC I is achieved by

silencing electrical activity in combination with exposure to proinflammatory cytokines, most notably IFNγ (Neumann, Cavalie et al.
1995; Neumann, Schmidt et al. 1997).

After induction of MHC I

expression, neurons are susceptible to antigen-specific lysis by activated
CD8 T cells (Medana, Gallimore et al. 2000).

CD8 T cells can kill

neurons by perforin-induced pore formation or through induction of
apoptosis by Fas ligand (Rensing-Ehl, Malipiero et al. 1996; Medana,
Gallimore et al. 2000).

Studies of CD8-mediated neuronal death have

relied on in vitro systems, using cultured neurons treated with cytokines
or chemicals to induce MHC I expression.
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There is still a need for

conclusive evidence of CD8 T cell mediated killing of neurons in vivo,
under pathologic conditions.

EAE is generally considered a CD4 T cell mediated illness, since adoptive
transfer of myelin-specific CD4 T cells is sufficient to induce disease in
naïve animals. However, CD8 T cells are equally capable of initiating
autoimmune demyelination. Demyelination can be generated by CD8 T
cells specific for myelin basic protein (MBP), and depends on the
production of the inflammatory cytokine IFNγ (Huseby, Liggitt et al.
2001). Adoptively transferred MBP-specific CD8 T cells are able to traffic
to the CNS and induce autoimmune neurologic disease in recipient
animals. Evidence from studies of MS patients supports the idea that
CD8 T cells play an important role in autoimmune demyelination (Ji and
Goverman 2007). CD8 T cells outnumber CD4 T cells by nearly ten-fold
in MS brains (Booss, Esiri et al. 1983).

In addition, CD8 T cells specific

for a protein expressed in oligodendrocytes were detected in the blood of
patients with MS but not control subjects (Niland, Banki et al. 2005).
These T cells were shown to lyse oligodendrocytes expressing the
appropriate MHC I allele in vitro, which suggests a possible mechanisms
for CD8 T cell mediated demyelination in patients.

CD8 T cell mediated neurologic disease occurs spontaneously in
transgenic mice with constitutive expression of the costimulatory
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molecule B7.2/CD86 on microglia (Zehntner, Brisebois et al. 2003;
Brisebois, Zehntner et al. 2006).

Expression of B7.2/CD86 on resident

CNS microglia creates a permanent immunostimulatory environment for
infiltrating

T

cells

that

naturally

leads

to

the

development

of

autoimmunity, highlighting the importance of inflammation behind the
blood-brain barrier to the generation of CNS autoimmune disease.

In

this model, CD8 T cells are the effector cells responsible for disease
pathogenesis, whereas CD4 T cells play an inhibitory role in disease
development.

In the absence of CD4 T cells, B7.2 transgenic mice

succumb to neurologic disease more rapidly, suggesting a protective role
for CD4 T cells in the activation of myelin-specific CD8 T cells (Brisebois,
Zehntner et al. 2006).

Regulatory CD4 T cells may help to suppress

CD8 T cells specific for CNS self-antigens, so that depletion of the CD4 T
cell repertoire in the B7.2 transgenic model serves to eliminate this
important inhibitory population, resulting in accelerated disease.

Regulatory T cells in the CNS
It is unclear how regulatory T cells react to inflammation in the CNS.
Pathologic inflammatory responses behind the blood brain barrier are
apparently able to overcome immune suppression induced by regulatory
T cells.

With regard to designing better therapeutic approaches, it is

important to determine whether regulatory T cells fail to traffic to the
target organ altogether, or if their mode of suppression is inhibited in the
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midst of an inflammatory response.

In mice that were immunized with

MOG to induce EAE, it was found that regulatory T cells persisted in the
CNS during the course of disease but were unable to prevent
demyelination by MOG-specific effector CD4 T cells (Korn, Reddy et al.
2007).

Regulatory T cells from the inflamed CNS effectively blocked

proliferation of effector CD4 T cells isolated from the spleen but could not
suppress proliferation of CNS effector T cells.

These results suggest

that during EAE, regulatory T cells in the periphery are functional
suppressors that traffic to the target organ. Once inside the inflamed
CNS, however, these cells are incapable of preventing autoimmune
mediated demyelination.

The failure on the part of CNS regulatory T

cells to suppress disease seemed to be due, in part, to the cytokine
milieu.

Effector CD4 T cells isolated from the CNS secreted large

amounts of pro-inflammatory cytokines, namely IL-6 and TNFα (Korn,
Reddy et al. 2007).

When peripheral regulatory T cells were exposed to

these two cytokines in vitro, their suppressive effect was abrogated.
This suggests that regulatory T cells in the inflamed CNS are ineffective
at limiting autoimmunity due to the production of pro-inflammatory
cytokines by effector cells within the target organ.

Inhibition of regulatory T cells within the inflamed CNS during EAE can
happen as a result of the local cytokine environment (Korn, Reddy et al.
2007).

Pro-inflammatory cytokines function to reverse the suppressive
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properties of regulatory T cells and allow for the escalation of an effective
immune response behind the blood brain barrier.

Normally, the brain is

bathed in TGF-β, a potent anti-inflammatory cytokine.

TGF-β acts to

maintain tolerance through regulation of lymphocyte proliferation and
survival, but it can also drive the differentiation of CD4 T cells into
regulatory T cells (Li, Wan et al. 2006).

Differentiation of CD4 T cells

into regulatory T cells via TGF-β is inhibited when inflammatory
cytokines, namely IL-6, are present. In the presence of both IL-6 and
TGF-β, CD4 T cells differentiate into Th17 cells (Veldhoen, Hocking et al.
2006) (Bettelli, Carrier et al. 2006).

Th17 cells contribute to many

inflammatory immune responses, and have been implicated in the
development of autoimmunity (Kikly, Liu et al. 2006).

Regulatory T cell

development and Th17 differentiation were shown to be mutually
exclusive pathways for naïve CD4 T cells (Bettelli, Carrier et al. 2006).
The presence of IL-6, and perhaps other inflammatory cytokines, is
therefore critical to shaping the CD4 T cell immune response.

Exposure

to inflammatory cytokines in the CNS, where there is constitutive
expression of TGF-β, would serve to promote the development of effector
rather than inhibitory CD4 T cells.
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Tolerance to CNS antigens
The CNS is considered an immune privileged site due to the presence of
the blood-brain barrier, which is designed to limit or restrain the
initiation of inflammatory immune responses.

Inflammation of the CNS

does occur, necessitating protection from autoimmunity via tolerance
induction to CNS antigens. CNS proteins are not hidden or ignored by
the immune compartment, and therefore mechanisms must exist to
safeguard against autoimmune neurologic disease.

Experimental

evidence of tolerance to CNS antigens has focused on the myelin
proteins, since EAE is the most prevalent model of CNS autoimmunity.
EAE is induced by priming T cells to myelin self-antigens, such as myelin
oligodendrocyte glycoprotein (MOG), proteolipid protein (PLP), and myelin
basic protein (MBP). All three proteins are components of myelin, but
tolerance to each is maintained in different ways.

Tolerance to the myelin proteins
Central tolerance ensures that PLP-specific T cells do not escape from the
thymus.

Thymic expression is restricted to a shorter splice variant of

PLP called DM20, so that T cells specific for epitopes within DM20 are
deleted during development.

C57BL/6 mice are resistant to PLP-

induced EAE because DM20 expression in the thymus is sufficient for
the elimination of PLP-specific clones.

SJL/J mice, conversely, are

highly susceptible to PLP-induced EAE since PLP-specific CD8 T cells in
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this strain respond to an epitope not found in DM20 and are not deleted
during development (Anderson, Nicholson et al. 2000; Klein, Klugmann
et al. 2000).

MOG is a minor component of CNS myelin, distinguished from other
myelin autoantigens by its immunodominance.

Tolerance to MOG is

weak, despite the generation of MOG-specific regulatory T cells in the
thymus (Korn, Reddy et al. 2007).

The frequency of MOG-specific

natural regulatory T cells is so low that these cells are unable to
suppress the activation of an immune response to MOG upon
immunization (Delarasse, Daubas et al. 2003; Korn, Reddy et al. 2007).
MOG-deficient animals mount an immune response to the protein that is
identical to that of their wild type counterparts, and MOG-specific T cells
from either wild type or MOG-deficient mice induce comparable disease
upon adoptive transfer (Delarasse, Daubas et al. 2003).

Tolerance to MBP happens both in the thymus and in the periphery.
Thymic expression is limited to a non-classical form of MBP (called golliMBP) that contains stretches of sequence identical to peripheral MBP
(Tranquill, Skinner et al. 1996; Cabbage, Huseby et al. 2007).

Because

certain epitopes of classic-MBP are missing, tolerance is also mediated by
thymic APCs that have acquired MBP from the periphery (Huseby, Sather
et al. 2001). Tolerance to MBP has been studied with regard to MBP-
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specific CD4 and CD8 T cells. CD4 T cells specific for an immunogenic
epitope

not

found

in

golli-MBP

(MBP121-140)

are

deleted

during

development through cross presentation of exogenous MBP by thymic
APCs (Huseby, Sather et al. 2001).

Negative selection does not

completely eliminate MBP-specific CD4 T cells from the repertoire,
however, due to developmentally regulated expression of MBP in the
periphery. In young mice (< 3 weeks old), a population of MBP-specific
CD4 T cells escapes thymic selection as a result of low levels of MBP
protein expression during the first 2 to 3 weeks of life (Huseby, Sather et
al. 2001).

In order to keep these self-reactive T cells in check, MBP-

specific CD4 T cells are suppressed in the periphery by regulatory T cells
(Cabbage, Huseby et al. 2007).

Pathogenic MBP-specific CD8 T cells that recognize an epitope contained
within golli-MBP (MBP79-87) are also tolerized (Huseby, Ohlen et al. 1999;
Perchellet, Stromnes et al. 2004).

To study the mechanisms behind

tolerance induction of MBP-specific CD8 T cells, two distinct T cell
receptor (TCR) transgenic mice were created, both with specificity for
MBP79-87. Despite their inherent similarities, these two T cell populations
were subject to very different forms of tolerance induction.

CD8 T cells

from one mouse were subject to central and peripheral tolerance
induction.

The majority of these cells were deleted in the thymus

during development, and those that escaped were inactivated in the
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periphery. CD8 T cells from the second TCR transgenic mouse bypassed
both forms of tolerance, as there was no deletion in either the thymus or
periphery. The most striking observation was the capacity of this second
T cell line to rescue other MBP-specific CD8 T cells from tolerance
induction. Based on their experimental results, the authors purpose a
model whereby certain MBP-specific CD8 T cells are able to strip APCs of
MBP peptide as a means of inducing tolerance (Perchellet, Stromnes et
al. 2004).

Tolerance to neuronal proteins?
Tolerance to myelin antigens is maintained by a variety of mechanisms,
and understanding how the immune system responds to myelin epitopes
is of great clinical significance with regard to designing better therapies
for the treatment of MS.

HuD is similar to the myelin proteins in that it

is specific to the nervous system. Unlike the myelin proteins, HuD is an
intracellular protein expressed exclusively by neurons. To date, there is
no evidence of tolerance to neuronal antigens.

The recognition of Hu-

expressing neurons by autoreactive T cells appears to be responsible for
neuronal degeneration in patients with the Hu syndrome.

Since all

SCLCs express the HuD antigen but only a fraction of patients mount a
detectable immune response to the protein, there are apparent
mechanisms responsible for preventing autoimmunity directed against
this antigen. Immune privilege to HuD could potentially occur through
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deletion of HuD-specific T cells from the repertoire.

If this were true,

patients with HuD-specific immune responses would necessarily avoid
central tolerance induction.

Alternatively, HuD-specific T cells that

circulate in the periphery may be ignorant of the protein, given the lack
of neuronal MHC expression under non-inflammatory conditions.
Reliance on immunologic ignorance is risky, however, as neurons are
able to upregulate MHC I expression during inflammation at the same
time as activated T cells are allowed entry to the CNS.

If HuD-specific T

cells avoid thymic deletion, suppression in the periphery via regulatory T
cells or anergy induction may serve to prevent the development of
neuronal autoimmunity.

To date, there is no evidence of tolerance to

neuronal antigens, nor a model to explain how such tolerance could be
generated.

Specific Aims
Patients with the Hu syndrome mount an immune response to HuD that
is evidenced by the presence of high titer antibodies to the protein in the
blood and CSF. Hu patients have impressive tumor immunity coupled
with severe neurologic disease, presumably mediated by HuD-specific T
cells that are able to target both tumor cells and neurons expressing the
Hu antigen.
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CD8 T cells are designed to monitor the intracellular compartment.
Given the intracellular location of the HuD antigen, HuD-specific CD8 T
cells are expected to be responsible for recognition and destruction of
HuD expressing cells in patients with the Hu syndrome. To better
understand

the

mechanisms

behind

CD8

T

cell

mediated

neurodegeneration, we sought to generate a mouse model of disease. An
exhaustive screen of the entire HuD peptide library was performed in
C57BL/6 in order to identify immunogenic epitopes of the HuD protein.
Potential epitopes were then assessed for their ability to be naturally
processed and presented by the immune system, which allowed for the
identification of the immunodominant CD8 T cell epitope of HuD.

HuD-

specific CD8 T cells were subjected to phenotypic and functional assays
in order to determine if these cells behave as typical cytotoxic T cells
capable of lysing HuD expressing targets.

In order to understand how

HuD-specific CD8 T cells mediate neurodegeneration, we established an
adoptive transfer model that enabled us to study HuD-specific CD8 T cell
trafficking to the CNS.

Maintaining tolerance is critical to protecting the body from destructive
immune responses against self-antigens.

Studies on the mechanisms

behind tolerance induction have focused primarily on peripheral
antigens. How the body maintains tolerance to neuronal proteins is
poorly understood.

To better understand this process, we sought to
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investigate tolerance induction to HuD. We also compared tolerance to
HuD versus its related family member HuA.

HuA shares high sequence

homology with HuD, however the protein is not neuron-specific but
ubiquitously expressed. The difference in expression between HuD and
HuA suggested that the two proteins might be subjected to different
forms of tolerance induction.

We hypothesized that tolerance to HuA

would be stricter compared to HuD since the protein is present in all
tissues and not restricted in expression to neurons.

Finally, we sought to identify clinically relevant human HuD epitopes in
order to better understand and diagnose anti-Hu syndrome.

Prior to

this study, no definitive proof of the presence of HuD-specific CD8 T cells
in patients with the Hu syndrome existed. In order to determine if HuDspecific CD8 T cells are expanded and activated during disease
pathogenesis, we sought to identify human immunogenic CD8 T cell
epitopes of HuD.

A comprehensive screen of the entire HuD peptide

library was performed over 8 human HLA MHC I alleles.

In this way,

two human CD8 T cell epitopes of HuD were discovered. Based on these
results, we designed HuD-specific tetramers in order to identify and
characterize HuD-specific CD8 T cells in patients.
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CHAPTER II. MATIERALS AND METHODS

Peptides.
The peptide library for iTopia screening was purchased from Jerini
Peptide Technologies (Berlin, Germany).

All other peptides were

purchased from American Peptide Company.

Mice.
Wild type C57BL/6, Thy1.1 (stock no. 000406), and Rag1-/- (stock no.
00216) mice were purchased from The Jackson Laboratory. HuD-/- mice
were obtained from H. Okano (ref PNAS paper). A2.1 transgenic HHD
mice were provided by Dr. Francois Lemonnier (Pasteur Institute). A2.1
transgenic AAD mice were purchased from The Jackson Laboratory.
AIRE mice were purchased from The Jackson Laboratory (stock no.
004743).

HuD Peptide Screen.
C57BL/6 mice were injected in the right footpad with a single HuD
peptide emulsified in Titermax adjuvant. To form the peptide emulsion,
75ul of HuD peptide at 10mg/mL in 50% DMSO was added to 75ul
ddH20.

This solution was then added to a sterile eppendorf tube

containing 150ul Titermax adjuvant. The tube was then vortexed for 30
minutes on high to form an emulsion. The emulsion was drawn into an
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insulin syringe and 50ul (approximately 125ug of peptide) was injected
per animal.

After 7 days, the animal was sacrificed and the right

popliteal and inguinal lymph nodes were removed. Lymph nodes were
ground between two sterile frosted glass slides to obtain a single cell
suspension.

CD8 T cells were isolated by MACS purification (Miltenyi

Biotec) and plated in a 20 hour IFNγ ELISPOT assay at 2 x 105 CD8 T
cells per well.

EL4 cells were added as stimulators at 5 x 104 per well

with 10uM peptide.

Immunizations.
For immunization with recombinant adenovirus, 6-8 wk old mice were
injected with 100ul purified adenovirus (109 PFU/mL) i.d. and treated
with Pertussis Toxin (Sigma) at days 0 and 2.
For EAE induction, 6-8 wk old C57BL/6 mice were immunized with
100ug MOG35-55 in CFA and treated with Pertussis Toxin on days 0 and
2.

Preparation of cells from the brain.
Brains were removed from mice perfused with 50 mL cold heparinized
saline and mechanically dissociated using a dounce homogenizer (VWR)
in HBSS w/ Ca and Mg (Gibco) containing 500ug/mL Collagenase D
(Roche), 5mg/mL Dispase II (Roche), 20U/mL DNase I (Roche) and 10mM
HEPES (Gibco).

The dissociated tissue in solution was incubated for 15
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minutes on a rotating neutator and then left to stand for an additional 15
minutes.

The resulting cell suspension was washed once in R-10 media

(RPMI 1640 supplemented with 10% FBS, nonessential amino acids,
sodium pyruvate, glutamine, 22-ME, gentamicin) and fractionated on a
30/37/70% percoll gradient at 1760rpm for 30 minutes.

Cells were

collected from the 37/70% interface.

Preparation of primary murine kidney cells.
Kidneys from adult mice were mashed using the back of a syringe and
pipetted until a single cell suspension was obtained. The cell suspension
was passed over a 70um cell strainer and washed in D-10 (DMEM
supplemented with 10% FBS, nonessential amino acids, sodium
pyruvate, glutamine, 22-ME, gentamicin) before plating in 10cm dishes.
Cultures were fed by replacing D-10 on days 4 and 7.

On day 7,

recombinant mouse IFNγ (R & D Systems) was added at 10U/mL. On
day 8, 10ul recombinant adenovirus at 109 PFU/mL was added to each
dish and the cells were harvested on day 9 for use in an IFNγ ELISPOT
assay.

Adenovirus production.
Recombinant adenoviruses expressing GFP, β-galactosidase, or HuD-GFP
was made by H. Okano. Recombinant adenovirus expressing HuA-GFP
was made by inserting the full-length HuA gene into the pAdenoTrack
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vector as previously described (He, PNAS 1998). Virus was produced by
transduction of HEK293 cells (ATCC) and purified using the Adenopure
Kit (Puresyn) according to the manufacturer’s instructions. Viral titers
were assessed by infection of HEK293 cells with serial dilutions of
purified virus followed by determination of the number of virally infected
cells after 20 hours by fluorescence or XGal staining.

Retrovirus production.
Retrovirus was produced by transfection of ecotropic Phoenix cells (a gift
from the DeLange Lab, Rockefeller University) with retroviral constructs
containing either HuD-GFP or GFP.

48 hours post transfection, viral

supernatant was harvested and used directly to infect target cells. 10mL
viral supernatant was added per 10cm dish of targets with polybrene
(5mg/mL).

Elispot assay.
CD8 cells were isolated from spleens or lymph nodes of immunized mice
using MACS purification (Miltenyi Biotec).

T cells were added to IFNγ

ELISPOT plates at the indicated concentrations along with stimulators
and incubated for 20. Cells were washed out of the ELISPOT plate using
a mild detergent followed by incubation with 1ug/mL biotin-conjugated
anti-IFNγ mAb.

Wells were developed using the Vectastain Elite Kit

according to the manufacturer’s instructions (Vector Laboratories).
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Colored spots represent IFNγ-secreting cells and are enumerated as spot
forming cells (SFCs) per 106 cells.

The ELISPOT plate evaluation was

performed by an independent evaluation service (Zellnet Consulting)
using an automated ELISPOT reader (Carl Zeiss).

Mouse dendritic cell preparation.
Bone marrow-derived DCs were prepared as previously described (Inaba
1992 JEM).

Briefly, bone marrow from tibia and femurs was lysed of

RBC and cultured in 6 well plates in R-10 in the presence of GM-CSF (ref
for J558L).

Fresh GM-CSF supplemented medium was added to the

wells on days 2, 4, and 6. On day 7, DCs were matured for 2 days with
recombinant mouse TNFα (R&D Systems) by harvesting and re-plating at
106/mL in 6 well plates with GM-CSF supplemented medium plus
recombinant mouse TNFα (125ng/mL).

Mouse antibody titers.
Sera from mice were diluted in 5% Dry Carnation Milk (Carnation Co.) in
.1% Tween/PBS and incubated with PVDF membrane strips containing
identical amounts of recombinant HuD antigen.
then

washed

thoroughly

in

.1%Tween/PBS

The membrane was
and

incubated

horseradish peroxidase-conjugated secondary antibody.

with

Signal was

visualized with a chemiluminescent substrate and a 35kD band
indicated the presence of anti-HuD antibody.
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Western blot with cell lysates.
106 cells were lysed in 100ul of passive lysis buffer (Promega). 25ul of
lysate (or 1ug rHuD) was run on a 10% SDS-polyacrilamide gel and
transferred to a PVDF membrane.

The membrane was blocked in 5%

Dry Carnation Milk (Carnation Co.) and incubated with Anti-Hu patient
sera (at 1:1000). The membrane was then washed thoroughly in
.1%Tween/PBS and incubated with horseradish peroxidase-conjugated
secondary antibody.

Signal was visualized with a chemiluminescent

substrate and a 35kD band indicated the presence of HuD protein.

Mouse CD8 T cell stimulations.
For in vitro stimulation, 2.5-3 x 107 splenocytes from adenovirusimmunized mice were incubated at 37°C in upright T25 culture flasks
(Corning) in R-10 (half of a spleen per flask) with .5uM peptide for 7
days. For further rounds of restimulation, splenocytes were plated in 24
well plates (2-6 x105 splenocytes per well) with peptide-pulsed feeder
cells in R-10 with 50 CU/mL recombinant human IL-2 (Chiron). Feeder
cells were prepared from spleens of naïve syngeneic mice by pulsing with
.5uM peptide for 1 hour at room temperature and irradiating at 3,000
Rads before plating (one spleen per 24 well plate).

43

Adoptive transfer.
For adoptive transfer experiments, mice received i.v. injections of in vitro
stimulated CD8 T cells (5 x 106 CD8/mouse) and DCs pulsed with
peptide (2 x 106 DC/mouse) along with IL-2 (6 injections of 105
CU/mouse i.p. every 12 hours) and Pertussis Toxin (400ng/mouse i.p.
on days 0 and 2). In vitro stimulation of CD8s was performed as
described. After 7 days of stimulation, CD8s were isolated by negative
selection using a CD8 T cell isolation kit (Miltenyi Biotec). The cells were
washed twice and resuspended at 2.5 x 107/mL in RPMI 1640DCs for i.v.
injection. DCs were prepared from bone marrow as described. For the
peptide pulse, TNFα-matured DCs were resuspended at 107 DCs/mL in
R-10 with 100uM peptide and incubated at room temperature for 1 hour,
shaking every 15 minutes.

The cells were then washed twice and

resuspended at 107/mL in RPMI 1640 for i.v. injection.

In Vivo CTL assay.
Mice received a single i.v. injection of target cells. The targets consisted
of two populations of cells in a 1:1 ratio:

irrelevant peptide-pulsed

syngeneic splenocytes labeled with .5uM CFSE (CFSElo) and relevant
peptide-pulsed syngeneic splenocytes labeled with 5uM CFSE (CFSEhi).
To prepare target cells, spleens from syngeneic mice were mashed with
the back of a syringe, decanted into two 15mL conical tubes, and
pelleted. To lyse erythrocytes, each pellet was resuspended in 5mL ACK
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lysis buffer (Gibco) and left at room temperature for 4 minutes. Lysis
was stopped by adding 8mL cold PBS to each tube. The cell suspensions
were combined in a 50mL conical tube, pelleted, resuspended in 10mL
warm R-10 and passed through a 70um cell strainer.

To pulse with

peptide, the cells were divided into two equal populations at a final
concentration of 107/mL in R-10.

One population was pulsed with

10uM cognate peptide and the other with 10uM irrelevant peptide at
37°C for 90 minutes, shaking every 15 minutes.

After 90 minutes,

excess peptide was removed by washing the cells three times in PBS.
The last wash was done in room temperature PBS. Cells were counted
and resuspended at 5 x 107 in warm (37°C) PBS. The irrelevant peptidepulsed population was labeled with .5uM CFSE (CFSElo) and the relevant
peptide-pulsed population with 5uM CFSE (CFSEhi).

To label the cells,

CFSE was added to the tubes, which were then inverted 6 times and
placed at 37°C for 10 minutes.

Labeling was stopped by adding ice cold

PBS to the tubes. The cells were washed once in cold PBS, and then
twice in room temperature PBS. The cells were resuspended at 108/mL
and combined in a 1:1 ratio. Mice received a single i.v. injection of 200ul
(107 CFSElo and 107 CFSEhi targets). 5-18 hours after target injection,
the spleens were removed and the amount of CFSElo versus CFSEhi
targets was quantitated by flow cytometry.
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Flow cytometry.
All surface antibodies were purchased from Beckton Dickinson. 106 cells
were resuspended in 100ul staining buffer (PBS containing 1% pooled
human serum, 1% FBS and 5% goat serum) and Fc blocked for 10
minutes using 1ug of anti-CD16/CD32 (FcγR11/III). 1ug of each specific
Ab was added directly to the cells and incubated for 15 minutes at 4°C.
Cells were then washed twice and analyzed using a BD FACSCalibur
instrument.

Tetramer staining
Surface antibodies were purchased from Beckton Dickinson. Tetramers
were obtained from Beckman Coulter Immunomics.

106 CD8 T cells

were resuspended in 100ul staining buffer (PBS containing 1% pooled
human serum, 1% FBS and 5% goat serum) and Fc blocked for 10
minutes using 1ug of anti-CD16/CD32 (FcγR11/III).

Cells were then

incubated with 1:50 dilution of tetramer for 20 minutes at room
temperature.
minutes.

1ug of antibody to CD8 was added for an additional 10

Cells were washed and analyzed immediately using a BD

FacsCaliber.

In Vitro CTL Assay.
Splenocytes from immunized animals were restimulated in 24 well plates
(one spleen divided evenly among 24 wells) for 6 days with .5uM peptide
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in R-10. On day 6, cells were harvested and resuspended at 5 x 106/mL
in R-10. For target cell preparation, 106 EL4 cells in 100ul of R-10 were
labeled with 10uM peptide plus 100uCi Cr51 for 1 hour at 37°C, shaking
every 10 minutes. EL4 cells were then washed 3 times in 1mL R-10 and
resuspended at 105/mL.

5 x 103 EL4 cells were plated per well in a

round bottom plate with serial dilutions of T cells, beginning with 5 x 105
T cells per well (100 T cells to 1 target cell) and ending at 3.125 x 104 T
cells per well (6.25 T cells to 1 target cell). Plates were spun at 300rpm
for 5 minutes and incubated at 37°C for 4.5 hours.

To harvest and

measure radioactivity from the CTL assay, 100ul of supernatant from
each well was pipetted into a sample plate for gamma measurement with
100ul gamma scintillation fluid.

RMA/S Assay.
RMA/S cells were plated in T-75 flasks at 5 x 105/mL in D-10 at 37°C for
9 hours and then placed at room temperature overnight with caps tightly
sealed.
106/mL.

RMA/S cells were harvested and resuspended in R-10 at 5 x
50ul of RMA/S cells were added to 50ul of peptide stock.

Peptides stocks were made at 100uM, 10uM, 1uM, 100nM, 10nM.
Duplicate tubes of RMA/S cells with peptide were incubated at room
temperature for 45 minutes. 4mL of room temperature PBS was added
to each tube and placed at either room temperature or 42°C for 5 hours.
For FACS staining, cells were resuspended in 50ul staining buffer (PBS
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containing 1% pooled human serum, 1% FBS and 5% goat serum) and
Fc blocked for 10 minutes at room temperature using 1ug of antiCD16/CD32 (FcγR11/III).

1ul of biotin anti-mouse H-2Db antibody

at.5mg/mL (BD Pharmingen, clone #28-14-8) was added and cells were
incubated at room temperature for 15 minutes. Cells were washed in
4mL room temperature PBS and resuspended in 100ul staining buffer
with 1ul streptavidin-PE at .5mg/mL (BD Pharmingen) and incubated for
10 minutes at room temperature.

Cells were washed in 4mL room

temperature PBS and analyzed by FACS.

iTopia screen.
Peptides were dissolved in 10mM DMSO and stored in aliquots at -20°C.
Screening assays were carried out according to the manufacturer’s
instructions using the provided reagents (Beckman Coulter).

In the

initial binding assay, peptides were added individually at .1mM to plates
coated with recombinant HLA molecules.

β2 microglobulin and FITC-

labeled anti-HLA class I were also added and the plates were then
incubated for 18 hours at 21°C before being washed and read by a
fluorescent

plate

reader (Ex 490nm, Em

520nm).

For affinity

measurements, peptides were assayed as described above over eight
serial dilutions.

For off-rate analysis, peptides were added to HLA

coated plates as described above, incubated at 21°C for 18 hours and
then washed and placed at 37°C for 0, .5, 1, 2, 4, 6, and 8 hours before
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being read. Data from each assay was analyzed in Prism using iTopia
software and iScores were generated from a proprietary formula that
takes into account measurements from all three assays.

Peripheral blood isolation.
Blood cells were collected by leukapheresis under a Rockefeller
University IRB-approved protocol with informed consent.
isolated

by

density

gradient

centrifugation

over

PBMC were

Ficoll-Hypaque

(Pharmacia), and separated into T cell enriched (ER+) and T cell depleted
(ER-) fractions by rosetting with neuraminidase-(Calbiochem, La Jolla,
CA) treated sheep red blood cells (Colorado Serum Company, Denver,
CO). These cell fractions were cryopreserved by freezing in 10% human
serum albumin/ 10%DMSO/RPMI.

Human dendritic cell culture.
Human dendritic cells (DC) were generated from peripheral blood
mononuclear cells (PBMC).

Briefly, ER- cells were cultured in the

presence of 100U/ml IL-4 (R&D Systems) and 100U/ml GM-CSF
(Immunex) for 6 days to generate immature DC. DC were harvested on
day 6 and plated with PGE2 and TNFa to induce maturation. After 2
days mDC were harvested and used for T cell stimulation.
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Human CD8 T cell isolation.
Isolation of T cell fractions has been described (Albert, Jegathesan et al.
2001).

Briefly, ER+ PBMC fractions were thawed incubated with anti-

CD8 MACS beads (Miltenyi Biotech, Auburn, CA) in 5%FBS/PBS,
washed and run through a magnetic column to isolate antibody bound
cells.

After washing the column, the positive cells were eluted by

plunging the column. For experiments with adenovirus-immunized mice,
spleens were harvested on day 13 and CD8 T cells were purified in a
manner similar to the human protocol using anti CD8a beads (Miltenyi).

In vitro stimulation of human peripheral blood T cells.
CD8 T cells were incubated with autologous mDC at a 30:1 ratio in 24
well plates with 10ug/ml peptide in AIM-V medium (Invitrogen)
supplemented with 5%FBS.

After two days of culture recombinant

human IL-2 (Chiron, CA) was added at 50IU/ml.

Tetramer staining on human T cells.
All

HLA-A0201

tetramers

were

obtained

from

Beckman

Coulter

Immunomics. 1.0 x 106 patient PBMC were incubated with 1:20 dilution
of tetramer for 20 minutes at room temperature. Antibody to CD8 was
then added to the cells for an additional 10minutes, washed and
analyzed immediately using a BD FacsCaliber. Cells were gated on the
CD8+ population.
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Quantitative western blot with human sera.
For confirmation of Hu antibody titers in patients, quantitative western
blot analysis with patient serum and recombinant HuD (rHuD) protein
was performed as described previously (Dalmau, Furneaux et al. 1990).
Briefly, 20ug of nickel-column purified his-tagged rHuD was loaded into
a large, single well of a SDS-polyacrylamide gel and transferred to PVDF
membrane.
patient

The blocked membrane was incubated with dilutions of

serum

and

horseradish

peroxidase-conjugated

secondary

antibody and the signal visualized with a chemiluminescent substrate.
The presence of reactivity to HuD, a 35kD protein, at a dilution greater
than 1:1000 indicates a high titer Hu patient. Sera from normal donors
were used as a negative controls and known positive patient samples as
positive controls.

Tetramer+ T cell sorting.
CD8 T cells were purified by positive selection (Miltenyi) from the frozen T
cell fractions of patient leukapheresates. 1 x106 CD8 T cells were plated
per well of a 24 well plate with 6000 peptide-pulsed, autologous mDC in
AIM-V medium (Invitrogen) containing 5% FBS. 24 hours after initiation
of the culture, IL-2 was added at 10U/ml. After 8-12 days of culture the
cells were harvested and incubated at 20 x 106/ml with a 1:20 dilution of
tetramer. The tetramer-positive population was sorted on a FACS Aria
instrument (BD BioSciences).

After sorting, cells were placed into
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culture in 96-well plates with autologous, peptide-pulsed PBMC and
50U/ml IL-2. After a recovery period of 8 days in culture, T cells were
used in ELISPOT and CTL assays.
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CHAPTER III. IDENTIFICATION OF THE IMMUNODOMINANT H-2b
CD8 T CELL EPITOPE OF HUD

Introduction
In order to study the mechanisms responsible for both T cell mediated
neurologic degeneration and neuronal tolerance induction, we first
sought to identify and characterize HuD-specific CD8 T cell clones.

A

comprehensive screen of the entire HuD peptide library was performed in
C57BL/6 mice, which lead to the identification of the immunodominant
CD8 T cell epitope of HuD. HuD-specific CD8 T cells were subjected to
phenotypic and functional assays in order to characterize these cells and
assess their ability to lyse HuD expressing targets in vitro and in vivo.

Results
Comprehensive screen to identify potential mouse H-2b HuD epitopes
To determine if HuD-specific CD8 T cells are present in the mouse H-2b
repertoire, we performed a comprehensive screen of the entire HuD
peptide library in C57BL/6 mice. C57BL/6 mice were chosen both for
their ability to preferentially generate cell mediated rather than humoral
immune

responses

and

because

most

immunologically

transgenic strains are bred onto the C57BL/6 background.

relevant
The HuD

peptide library consisted of 386 overlapping nonamers, including
peptides derived from each known splice variant of the protein. In order
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to ensure that all HuD peptide-specific CD8 T cells present in the H-2b T
cell repertoire were identified, we chose an aggressive immunization
strategy that allowed for the expansion of peptide-specific CD8 T cells
without the need for an APC or CD4 T cell help. Mice were immunized
with each individual HuD peptide emulsified in Titermax adjuvant. After
7 days, CD8 T cells were isolated from the draining lymph nodes and
assessed for their ability to secrete IFNγ in an ELISPOT assay with
cognate peptide-pulsed syngeneic stimulators. As a negative control,
syngeneic stimulators were pulsed with an irrelevant peptide.

The

secretion of IFNγ in response to cognate peptide indicated that there were
HuD-specific CD8 T cells present in the T cell repertoire. After screening
the entire peptide library in this fashion, we identified 7 potential HuD
CD8 T cell epitopes (Fig 1a).

Identification of the immunodominant H-2b HuD epitope
We next sought to identify naturally processed and presented HuD CD8
T cell epitopes from these 7 potential peptides.

The presence of CD8 T

cells specific for a given peptide in the H-2b repertoire does not by itself
demonstrate natural processing and presentation.

In order to show

natural processing and presentation, mice were immunized with a
replication-deficient recombinant adenovirus expressing full length HuD
to allow for in vivo processing and presentation of HuD epitopes onto
MHC I molecules and subsequent CD8 T cell priming. To further
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Fig 1. p321 is the immunodominant CD8 T cell epitope of HuD. (a)
The entire HuD peptide library was screened in C57BL/6 mice.

7

peptides (in bold) were identified as potential CD8 epitopes. (b) C57BL/6
mice

were

immunized

with

AdVHuD

plus

PTx.

13

days

after

immunization, splenocytes were divided into 8 in vitro stimulation
cultures and stimulated with each of the 7 HuD peptides or the
immunodominant Bgal epitope p96. CD8 T cells were purified from
stimulation cultures and plated (104 T cells/well) with cognate or
irrelevant peptide-pulsed irradiated EL4 cells (5 x 104/well) in an IFNg
ELISPOT assay. (c) As a control for in vitro priming, C57BL/6 mice were
immunized with AdVBgal + PTx and stimulated in vitro with each of the 7
potential HuD epitopes or Bgal p96 and assayed for IFNg secretion as in
(b).
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Fig. 1
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expand the population of peptide-specific CD8 T cells after adenovirus
immunization, splenocytes from immunized animals were stimulated in
vitro for 7 days with each of the 7 potential HuD epitopes. CD8 T cells
were then isolated from stimulation cultures and T cell activation was
assessed in an IFNγ ELISPOT assay using cognate peptide-pulsed cells as
stimulators (Fig 1b).

In order to ensure that a positive CD8 T cell

response was the result of bona fide natural processing and presentation
in vivo and not due to in vitro priming, we immunized a second group of
mice with a replication-deficient recombinant adenovirus expressing the
neo-antigen β-galactosidase (β-gal).

Splenocytes from β-gal immunized

mice were stimulated in vitro with each of the 7 potential HuD epitopes
and T cell activation was assessed in an IFNγ ELISPOT assay using
cognate peptide-pulsed cells as stimulators (Fig 1c). Of the 7 potential
HuD epitopes, peptides 296 and 321 were able to prime CD8 T cells in
vivo after adenovirus-HuD immunization.
elicited

IFNγ

secretion

after

Neither of these peptides

immunization

with

adenovirus-β-gal,

excluding the possibility of in vitro priming. Based on the strength of the
immune response to each of these two peptides, we concluded that
peptide 321 (p321) represents the immunodominant epitope of HuD.
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Fig 2.

Pertussis toxin (PTx) is required for HuD-specific CD8 T cell

priming.

C57BL/6 mice were immunized with AdVHuD alone (a) or

AdVHuD plus PTx (b). 13 days after immunization, splenocytes were
stimulated in vitro with p321. CD8 T cells were purified from stimulation
cultures and plated (104 T cells/well) with cognate or irrelevant peptidepulsed dendritic cells (7 x 103/well) in an IFNg ELISPOT assay.
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Pertussis Toxin is required for the generation of IFNγ-secreting HuD-specific
CD8 T cells
Immunization with adenovirus-HuD followed by in vitro stimulation with
peptide proved to be an effective priming regiment for HuD-specific CD8
T cells only if pertussis toxin was injected together with adenovirus.
Immunizing with adenovirus-HuD alone did not generate IFNγ-secreting
HuD-specific CD8 T cells even after p321 stimulation in vitro (Fig 2).
Historically, pertussis toxin (PTx) has been used in the induction of EAE.
EAE is arguably the most studied example of autoimmunity in the CNS,
and thus it seemed logical to look to this model of disease for guidance in
the generation of an immune response to HuD.

PTx was historically

thought to act on EAE by serving to break down the blood brain barrier.
We now understand that PTx increases adhesion molecule expression,
thereby initiating leukocyte infiltration into the brain (Kerfoot, Long et al.
2004).

Recent work has shown that PTx also induces maturation of

dendritic cells, which promotes the differentiation of effector T cells (Hou,
Wu et al. 2003).

In our attempt to generate cytotoxic CD8 T cells

specific for HuD, this last effect was especially relevant.

In order to

determine if PTx could assist in the production of HuD-specific effector T
cells,

mice

were

immunized

with

adenovirus-HuD

alone

or

in

combination with PTx. Mirroring the EAE induction protocol, we injected
PTx intraperitoneally (i.p.) on day 0 and day 2.

Splenocytes from

immunized mice were then stimulated with p321 in vitro and assessed for

59

their ability to secrete IFNγ in an ELISPOT assay.

Mice that received

adenovirus-HuD alone were unable to produce IFNγ-secreting CD8 T cells
specific for HuDp321, whereas mice receiving PTx in combination with
adenovirus-HuD generated a robust peptide-specific response (Fig 2).

Db MHC I molecules present p321
In order to further characterize HuDp321-specific CD8 T cells, we defined
their MHC restriction.

This was an important issue to address with

regard to designing tetramers for these cells. A tetramer consists of a
fluorochrome-tagged complex of four MHC I:peptide molecules and is
able to bind specifically to the T cell receptor on a CD8 T cell. Initially,
we were able to predict the MHC I specificity of p321 by using publicly
available prediction algorithms of peptide-MHC interactions. Based on its
amino acid sequence, both the Bioinformatics and Molecular Analysis
Section of the National Institutes of Health (BIMAS) and the University of
Tubingen (SYFPEITHI) predicted p321 to bind Db MHC I.

To formally

prove its MHC I restriction, we took advantage of a transgenic mouse
strain that does not express Kb but retains expression of Db MHC I.
H2bm1 mice are deficient in Kb expression due to a point mutation at the
H-2 Kb locus.

Primary kidney cells derived from either wild type

C57BL/6 mice or H2bm1 mice were pulsed with peptide in order to
determine the MHC I restriction of p321.

As a positive control, we

pulsed these same sets of stimulators (wild type versus H2bm1 kidney
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cells) with the β-gal epitope p96, which binds to Kb MHC I molecules.
Peptide-pulsed kidney cells were used as stimulators in an IFNγ ELISPOT
assay with 3x-restimulated HuDp321-specific and β-galp96-specific CD8
T cells (Fig 3). As expected, β-galp96-specific CD8 T cells responded to
wild type p96 pulsed stimulators but not to H2bm1 pulsed stimulators.
HuDp321-specific CD8 T were able to respond equally well to wild type
and H2bm1 p321 pulsed stimulators, confirming the prediction that p321
is a Db restricted CD8 T cell epitope.

Characterization of HuDp321-specific T cells
Next, we assessed the affinity of HuDp321-specific CD8 T cells.

Using

twice re-stimulated HuDp321-specific CD8 T cells, we measured the
ability of these cells to recognize serial dilutions of peptide pulsed onto
syngeneic dendritic cells in an IFNγ ELISPOT assay (Fig 4). HuDp321specific CD8 T cells were able to secrete IFNγ in response to 10-9 M
peptide, but below this concentration the response was lost.

Twice re-

stimulated β-galp96-specific CD8 T cells were also able to recognize 10-9
M peptide (data not shown).

Thus, HuDp321-specific CD8 T cells are

relatively high affinity T cells. Finally, we asked if HuDp321-specific CD8
T cells display a characteristic cell surface phenotype upon activation.
We chose to look at CD25, CD69 and CD62L as markers of T cell
activation. CD25 is the IL-2 receptor α chain and is up-regulated on
activated T cells. CD62L (or L-selectin) is a member of the selectin
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Fig 3.

HuD p321 is presented on Db MHC I. (a) Primary kidney cells

from C57BL/6 mice (Db+/ Kb+) or transgenic Bm1 mice (Db+/ Kb- ) were
irradiated and pulsed with p321 or p96 and used as stimulators in an
IFNg ELIPOST assay (5 x 104/well) with 3x restimulated HuD p321specific or Bgal p96-specific CD8 T cells (104/well).
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Fig 4. HuDp321-specific CD8 T cells are high affinity T cells.
HuDp321-specific CD8 T cells (2x restimulated) were plated in an IFNg
ELISPOT assay (1.5 x 104/well) with C57BL/6 DC pulsed with serial
dilutions of cognate peptide or NP as a negative control (104/well).
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family of cell adhesion molecules and plays an important role in
lymphocyte homing to peripheral lymph nodes.

It is a glycoprotein

expressed on naïve T cells and down-regulated upon activation-induced
differentiation. CD69 is an early activation antigen expressed by T cells.
After stimulating HuDp321-specific CD8 T cells in vitro with cognate
peptide for 7 days, we looked at expression of these three surface
markers by flow cytometry (Fig 5). As expected, both CD25 and CD69
were up-regulated whereas CD62L was down-regulated on activated
HuDp321-specific T cells.

In comparison, naïve T cells expressed no

CD25 or CD69 but had high expression of CD62L, whereas activated βgalp96-specific CD8 T cells displayed an identical cell surface phenotype
to activated HuDp321-specific T cells (Fig 5).

Thus, HuDp321-specific

CD8 T cells display a characteristic cell surface phenotype upon
activation.

Cytolytic function of HuDp321-specific T cells in vitro
Having established that HuDp321-specific cells are relatively high affinity
CD8 T cells with a characteristic activated cell surface phenotype, we
next asked if they could function as effector CD8 T cells capable of lysing
targets expressing cognate peptide.

The ability of CD8 T cells to lyse

target cells in an antigen-dependent manner is a critical function of the
immune system and an important part of the body’s defense against
intracellular pathogens. Activated CD8 T cells are aptly referred to as
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Fig

5.

Stimulated

HuDp321-specific

CD8

T

cells

display

a

characteristic cell surface phenotype. In vitro stimulated HuDp321specific or Bgalp96-specific CD8 T cells were stained on day 7 for CD25,
CD62L, and CD69.

Naïve T cells from the spleen of a C57BL/6 were

used as a control. Plots are gated on CD8+ cells.
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cytotoxic T lymphocytes (CTL).

We first examined the lytic ability of

HuDp321-specific cells in vitro, using chromium labeled peptide-pulsed
syngeneic cells as targets (Fig 6).

Splenocytes from adenovirus-HuD

immunized animals were stimulated in vitro with p321. Activated T cells
were then cocultured with targets pulsed with cognate or irrelevant
peptide.

For comparison, β-galp96-specific T cells were assessed for

their lytic ability in an identical assay (Fig 6). Both HuDp321-specific T
cells and β-galp96-specific T cells were able to lyse target cells expressing
cognate peptide.

β-galp96-specific T cells had a greater percent lysis

compared to HuDp321-specific T cells, however this is explained by the
larger number of p96-specific T cells present after in vitro stimulation.
Stimulating splenocytes from adenovirus-HuD immunized animals in
vitro with p321 results in approximately 1% p321-specific CD8 T cells
(Fig 7).

In contrast, after in vitro stimulation of adenovirus-β-gal

splenocytes with p96, 5-10% of the CD8 T cells are specific for p96 (Fig
7).

For our in vitro CTL assay, bulk cells from in vitro stimulation

cultures were counted and plated and thus there were roughly 10-fold
more p96-specific CD8 T cells than p321-specific CD8 T cells per well.
Given the results of the in vitro CTL assay, we can conclude that
HuDp321-specific T cells are functional effectors capable of lysing target
cells in an antigen-dependent manner.
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Fig 6. HuDp321-specific CD8 T cells can kill in vitro. C57BL/6 mice
were immunized with AdVHuD plus PTx or AdVBgal plus PTx. 13 days
after immunization, splenocytes were stimulated in vitro with cognate
peptide (HuDp321 or Bgalp96). On day 6, cells from stimulation cultures
were plated with chromium labeled peptide-pulsed EL4 cells at the
indicated E:T ratios. EL4 cells were pulsed with 10uM Bgalp96 or 10uM
HuDp321. In red, three individual AdVHuD-immunized mice. In blue,
one representative AdVBgal-immunized mouse.
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Fig 7.

Frequency of in vitro stimulated CD8 T cells. C57BL/6 mice

were immunized with AdVHuD plus PTx (a) or AdVBgal plus PTx (b). 13
days after immunization, splenocytes were stimulated in vitro for 7 days
with cognate peptide (HuDp321 or Bgalp96). CD8 T cells were purified
from stimulation cultures and stained with Bgalp96 tetramer or
HuDp321 tetramer. Plots are gated on CD8 T cells.
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Cytolytic function of HuDp321-specific T cells in vivo
If HuD-specific CD8 T cells are responsible for generating neuronal
autoimmunity in anti-Hu syndrome, these cells must be capable of
functioning as cytotoxic T cells in vivo.

In order to examine the lytic

ability of HuD-specific cells in vivo, we adoptively transferred T cells into
a syngeneic host and measured their ability to lyse a population of
peptide-pulsed target cells.

Targets consisted of C57BL/6 splenocytes

labeled with carboxyfluoroscein succinimidyl ester (CFSE) and pulsed
with peptide. Two populations of target cells were injected into the host,
a cognate peptide-pulsed population and an irrelevant peptide-pulsed
control population. These two populations were distinguished by their
CFSE

intensity

(p321-pulsed

targets

were

labeled

with

a

high

concentration of CFSE [CFSEhi] and p96-pulsed targets were labeled with
a low concentration of CFSE [CFSElo]) and were mixed at a 1:1 ratio
before being injected intravenously. 6 to 18 hours after target injection,
the host animal was sacrificed and the amount of each target population
remaining in vivo was measured by flow cytometry (Fig 8).

In a host that

received HuDp321-specific CD8 T cells, the p321-pulsed CFSEhi
population was reduced, demonstrating in vivo antigen-dependent lysis
by HuDp321 T cells.

Similarly, in a host containing β-galp96-specific T

cells, the p96-pulsed CFSElo population was eliminated.

Mirroring the

results of our in vitro CTL assay, β-galp96-specific T cells had a greater
amount of specific lysis compared to HuDp321-specific cells, again due
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to the increased numbers of p96-specific cells after in vitro stimulation.
In order to enhance the effector function of our transferred T cells, we
injected mature C57BL/6 dendritic cells (DC) pulsed with p321 along
with stimulated HuDp321-specific CD8 T cells. We reasoned that this
peptide-pulsed DC population would provide an in vivo re-stimulation for
HuDp321-specific T cells, thereby increasing their numbers and
enhancing the amount of lysis.

Host animals were injected with in vitro

stimulated HuDp321-specific cells in combination with DCs pulsed with
p321 or, as a control, DCs pulsed with p96. Similarly, a second group of
animals was injected with stimulated β-galp96-specific T cells together
with peptide-pulsed DCs.

The addition of cognate peptide-pulsed DCs

increased the amount of lysis by both HuDp321-specific T cells and βgalp96-specific T cells (Fig 8). This increase was not due to non-specific
stimulation of T cells by DCs, as the addition of irrelevant peptide-pulsed
DCs did not increase the lytic ability of our T cells. We chose to assess
target lysis by T cells in vivo in two different strains of mice: wild type
C57BL/6 mice and transgenic Rag-/- animals that are deficient for the
Rag-1 gene and therefore lack mature T cells and B cells. Rag-/- mice
were used because we were concerned that the endogenous T cell
repertoire, which includes regulatory T cells, could potentially serve to
inhibit our transferred cells and suppress their effector function.

Our

initial in vivo CTL experiment used the Rag-/- strain in order to provide
an empty host devoid of endogenous T cells (Fig 8). Transferred
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Fig 8. DC pulsed with cognate peptide enhance killing by HuDp321specific CD8 T cells in vivo.

5 x 106 HuDp321-specific or Bgalp96-

specific in vitro stimulated CD8 T cells were adoptively transferred into
Rag-/- mice with 2 x 106 C57BL/6 bone marrow derived DC pulsed with
cognate or irrelevant peptide. Mice also received PTx and IL-2. Nine days
post

transfer,

mice

were

injected

with

CFSE-labeled

syngeneic

splenocytes pulsed with p321 or p96. p321-pulsed targets were labeled
with a high fluorescence intensity and p96-pulsed targets were labeled
with a low fluorescence intensity.

7 hours after target injection,

splenocytes were analyzed by FACS for in vivo target cell lysis
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HuDp321-specific CD8 T cells were efficient at lysing targets in a Rag-/host. In order to examine the issue of suppression by the endogenous
C57BL/6 T cell repertoire, we performed a second experiment, comparing
the lytic ability of HuDp321-specific T cells in a Rag-/- versus a wild type
host (Fig 9).

Our transferred cells were equally potent cytotoxic effectors

in either strain of mice.

We concluded that once activated, HuDp321-

specific CD8 T cells are able to function as cytotoxic effectors in an
immune-competent host.

Summary
We have shown that there are HuD-specific CD8 T cells present in the H2b repertoire, and that peptide 321 represents the immunodominant
epitope of the HuD protein.

Peptide 321 is a Db restricted epitope, and

HuDp321-specific CD8 T cells are high affinity cells that display a
characteristic

cell

surface

phenotype

upon

in

vitro

stimulation.

Immunization with recombinant adenovirus-HuD followed by in vitro
peptide stimulation allowed for the activation of HuDp321-specific CD8 T
cells.

Pertussis toxin was also required for successful priming in vivo,

since immunization with adenovirus-HuD alone did not result in
HuDp321-specific T cell activation, even after in vitro stimulation. In vitro
stimulated HuD-specific CD8 T cells were shown to be functional
cytotoxic T cells capable of secreting IFNγ and lysing target cells in an
antigen-dependent manner. There was no loss of lytic ability in vivo
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Fig 9. HuD p321-specific CD8 T cells can kill in vivo. (a) 5 x 106 HuD
p321-specific in vitro stimulated CD8 T cells were adoptively transferred
into Rag-/- mice with 2 x 106 C57BL/6 bone marrow derived DC pulsed
with p321. Mice also received PTx and IL-2. Eight days post transfer,
mice were injected with CFSE-labeled syngeneic splenocytes pulsed with
p321 or p96. p321-pulsed targets were labeled with a high fluorescence
intensity and p96-pulsed targets were labeled with a low fluorescence
intensity.

6 hours after target injection, splenocytes were analyzed by

FACS for in vivo target cell lysis. (b) as in (a) except that WT C57BL/6
mice were used as recipients of adoptively transferred HuDp321-specific
CD8 T cells.
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when stimulated HuD-specific CD8 T cells were transferred into a wild
type host, suggesting that once expanded and activated, these cells are
able to overcome any form of immune suppression.
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CHAPTER IV. TOLERANCE TO HUD IN THE MOUSE

Introduction
The immune system is designed to distinguish self proteins from foreign
antigens.

Effective immune responses to self tissues are necessarily

avoided in order to guard against the development of deleterious
autoimmune disease.

The central nervous system is not ignored by the

immune system, as activated T cells are allowed access to the CNS in
order to defend against infection.

Immunosurveillance of the CNS poses

the risk of developing autoimmune neurodegeneration mediated by
neuron-specific T cells. Tolerance induction to neuronal antigens is
poorly understood.

Patients with anti-Hu syndrome have aggressive

neuronal autoimmunity, presumably mediated by HuD-specific T cells.
The fact that a majority of SCLC patients fail to mount an immune
response to HuD despite the presence of this protein in all tumors
suggests that tolerance induction to HuD is normally maintained.

In

patients with the Hu syndrome, tolerance would necessarily be broken to
allow autoreactive lymphocytes to target HuD expressing neurons.
Having identified and characterized HuD-specific CD8 T cells in mice, we
sought

to

investigate

tolerance induction

to

HuD.

Our

initial

experiments showed that in vitro stimulation with peptide subsequent to
immunization with full-length protein and pertussis toxin was required
to detect activated HuD-specific CD8 T cells.
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The need for in vitro

stimulation and PTx suggested that HuD-specific CD8 T cells are subject
to tolerance induction. In order to formally show tolerance to HuD, we
took advantage of HuD-deficient transgenic mice.

In addition, we

sought to compare tolerance induction to HuD versus HuA.

HuA is a

closely related Hu family member with high sequence homology to HuD,
however the protein is not neuron-specific but ubiquitously expressed.
Given the difference in expression between HuD and HuA, we reasoned
that the two proteins might undergo different forms of tolerance
induction.

We hypothesized that tolerance to HuA should be stricter

compared to HuD since the protein is present in all tissues and not
restricted in expression to neurons.

Results
HuDp321 specific T cells do not secrete IFNγ ex vivo after adenovirus-HuD
immunization
IFNγ secretion is a hallmark of T cell activation. We have already shown
that HuDp321-specific CD8 T cells are capable of secreting IFNγ upon
immunization with recombinant adenovirus, however these results relied
on pertussis toxin treatment and in vitro stimulation with peptide.
Immunization followed by stimulation ex vivo, outside of the host’s
normal immune system, serves to release cells from any inhibition felt in
vivo.

We have shown activation of HuD-specific CD8 T cells subsequent

to removing these cells from their in vivo environment (in vitro stimulated
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HuDp321-specific CD8 T cells secrete substantial amounts of IFNγ in
response to cognate peptide and are able to lyse target cells in an
antigen-dependent manner), however we have yet to assess the activation
of these cells directly after immunization with adenovirus-HuD.

An

inability to activate HuD-specific CD8 T cells in vivo would imply immune
tolerance to the HuD protein. In order to determine if HuDp321-specific
T cells can be activated in vivo, we immunized mice with adenovirus-HuD
together with pertussis toxin and isolated CD8 T cells from the spleen.
CD8 T cells were plated directly in an IFNγ ELISPOT assay with cognate
peptide-pulsed stimulators (Fig 1). As a control, mice were immunized
with adenovirus-β-gal.

β-gal is a neo-antigen and therefore not subject

to tolerance induction in vivo.

After immunization with adenovirus-β-gal

without in vitro p96 stimulation, we were able to show robust IFNγ
secretion by β-galp96-specific CD8 T cells.

In contrast, we saw no IFNγ

secretion by HuDp321-specific CD8 T cells after immunization with
adenovirus-HuD (Fig 1). The inability to activate HuD-specific T cell in
vivo after immunization suggests that mice are tolerized to the HuD
protein.

HuDp321 specific T cells expand in vivo after immunization with HuD
Because we can isolate T cells from mice immunized with adenovirusHuD and generate IFNγ-secreting CD8 T cells after p321 stimulation in
vitro, we can be certain that a population of HuD-specific CD8 T cells
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Fig 1.

HuD p321-specific CD8 T cells do not secrete IFNg directly

ex vivo after adenovirus-HuD immunization.

C57BL/6 mice were

immunized with AdVHuD or AdVBgal (i.d.) + PTx . 13 days later, CD8 T
cells were isolated from the spleen and plated in an IFNg ELISPOT assay
(2 x 105/well) with mDC pulsed with 10uM peptide (7 x 103/well).
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exists in the H-2b repertoire. The fact that we cannot see IFNγ secretion
directly ex vivo after immunization implies that there are tolerance
mechanisms acting to suppress HuD-specific T cell activation.

Both

central and peripheral tolerance mechanisms protect the body from autoreactive immune responses.

Central tolerance serves to delete any self-

reactive T cell clones from the repertoire during development in the
thymus, whereas peripheral tolerance actively suppresses those selfreactive T cells that escape thymic deletion to circulate in the periphery.
Because we were unable to detect HuDp321-specific T cells by IFNγ
secretion directly after immunization, we instead used tetramer to
visualize and quantify these cells in mice after adenovirus-HuD
immunization.

For comparison, a second group of mice was immunized

with influenza virus (e.g. flu). We measured the number of HuDp321specific CD8 T cells or NP-specific CD8 T cells by tetramer directly ex vivo
and after in vitro stimulation (Fig 2).

NP is a Db restricted CD8 T cell

epitope of influenza. Splenocytes for adenovirus-HuD or flu immunized
animals were stained directly ex vivo with both HuDp321 tetramer and
NP tetramer.

We observed the expected frequency of NP-specific T cells

(1.5% of the total CD8 T cell repertoire), and we could expand this
population by in vitro stimulation with NP.

In comparison, after

adenovirus-HuD immunization we observed .04% HuDp321-specific CD8
T cells. This population could be expanded in vitro by p321 stimulation.
Expansion of HuDp321-specific T cells depended on the presence of HuD
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Fig 2.

HuDp321-specific CD8 T cells expand in vivo after

immunization with adenovirus-HuD. C57BL/6 mice were immunized
with either AdVHuD + PTx or influenza virus (naïve mice were left
untreated). 15 days after immunization, CD8 T cells were isolated from
the spleen and stained directly ex vivo with anti-CD8 antibody and
tetramer.

Each population of CD8 T cells was stained with NP-Db

tetramer and p321-Db tetramer separately.

Splenocytes from each

mouse were also stimulated in vitro with cognate peptide for 7 days.
Naïve mice were stimulated with p321.

CD8 T cells from in vitro

stimulation cultures were stained with anti-CD8 antibody and tetramer.
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in vivo, as in vitro stimulation of naïve splenocytes with p321 did not
generate a population of HuDp321-specific cells (Fig 2).

Thus, there is

visible, albeit slight, response in vivo of HuDp321-specific CD8 T cells
after immunization, but this population is readily expanded upon in vitro
stimulation with antigen.

HuAp268-specific T cells are absent from the H-2b repertoire
To better understand the mechanisms behind tolerance to the Hu
proteins, we compared the immune response to HuDp321 versus its
homologous epitope in HuA, p268. HuAp268 differs from HuDp321 at a
single amino acid position (Fig 3a). The anchor residues that stabilize the
peptide-MHC interaction are conserved between the two peptides so that
both should bind MHC I with similar affinity. In order to ensure that
HuAp268 binds efficiently to MHC I molecules, we assessed the affinities
of p268 versus p321 using RMA/S cells incubated with serial dilutions of
peptide (Fig 3b). HuAp268 had a higher affinity for Db MHC I compared
to HuDp321, which bound Db with similar affinity compared to the
positive control peptide NP.

Unlike HuD, HuA is not confined to

neurons but is ubiquitously expressed. We hypothesized that immune
tolerance to this protein would be stricter compared to a neuron-specific
protein like HuD.

To determine if HuAp268-specific CD8 T cells are

present in the H-2b repertoire or deleted as a result of central tolerance
induction, we immunized C57BL/6 mice with Titermax-peptide and
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Fig 3.

HuA p268 binds with high affinity to Db MHC I. (a) HuDp321

and homologous peptides in HuA, HuB, HuC.

(b) RMA/S cells were

incubated with serial dilutions of peptide and stained for Db MHC I. HuD
p321 and its homologous epitope in HuA (p268) were assayed. The A2.1
epitope of influenza (M1) was used as a negative control. The Db epitope
of influenza (NP) was used as a positive control.
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looked for IFNγ secretion by CD8 T cells in an ELISPOT assay (Fig 4a).
Whereas HuDp321-specific and NP-specific T cells were clearly present in
the repertoire, HuAp268 cells were absent.

The absence of HuAp268-

specific T cells suggests that these cells were centrally deleted.

Given

the high affinity of p268 for MHC I, and its sequence homology to p321,
we can assume that this peptide is naturally processed and presented.
The complete absence of HuAp268 cells from the T cell repertoire is
indicative of central tolerance to HuA.

HuDp321 specific T cells do not cross-react with HuA
Patients with the Hu syndrome succumb to autoimmunity directed
against the nervous system but not against peripheral tissues, implying
that the immune response to HuD does not cross-react with HuA. To
investigate cross-reactivity to HuA, we asked if HuDp321-specific CD8 T
cells are able to respond to primary kidney cells infected with
adenovirus-HuA

(Fig

4b).

HuDp321-specific

CD8

T

cells

were

restimulated three times in vitro and plated in an IFNγ ELISPOT assay
with kidney cells infected with either adenovirus-HuA, adenovirus-HuD,
or a control adenovirus expressing GFP. Only kidney cells infected with
adenovirus-HuD were able to elicit IFNγ secretion from HuDp321-specific
CD8 T cells. The lack of cross-reactivity to HuA is in accordance with
clinical data and supports our model of autoimmunity directed
exclusively against neurons.
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Fig 4.

HuA p268-specific CD8 T cells are absent from the H-2b

repertoire. (a) C57BL/6 mice were immunized with individual peptides
(NP, HuA p268, or HuD p321) in titermax adjuvant. 7 days later,
draining lymph node CD8 T cells were plated in an IFNg ELISPOT assay
(2 x 105/well) with peptide-pulsed EL4 cells (5 x 104/well).

(b) HuD

p321-specific CD8 T cells (3x restimulated) were plated in an IFNg
ELISPOT assay (104/well) with primary kidney cells infected with
recombinant adenovirus (5 x 104/well).
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Mice are tolerized to HuD
We have shown that HuD-specific CD8 T cells exist in the H-2b
repertoire, although there appears to be tolerance to the protein since in
vitro stimulation is required for their activation.

To definitely prove

tolerance to HuD, we took advantage of the transgenic HuD-deficient
mouse (Akamatsu, Fujihara et al. 2005). HuD-/- mice were generated by
targeted disruption of the HuD gene. Phenotypically, HuD-/- pups are
indistinguishable from their wild type littermates. By 4-8 weeks of age, a
70-80% of HuD-/- mice exhibit an abnormal clasping of the hind limbs
when suspended by the tail, suggesting cortical and/or basal ganglia
defects. Immunologically, the absence of HuD in vivo would prevent any
form of tolerance to the protein.

If HuDp321-specific CD8 T cells

experience tolerance induction, then elimination of the HuD protein
should result in efficient expansion and activation of these cells in vivo.
To assess tolerance to HuD, we immunized HuD-/- versus wild-type mice
with adenovirus-HuD and measured IFNγ secretion by HuDp321-specific
CD8 T cells directly ex vivo (Fig 5a).

HuDp321-specific CD8 T cells from

HuD-deficient mice exhibited a strong response ex vivo, whereas HuD+/+
mice were unable to generate activated HuDp321-specific cells directly
after immunization (Fig 5a).

To ensure that the lack of an ex vivo

response in wild type mice was not due to an ineffective immunization,
portions of the spleens from individual mice were stimulate in vitro with
p321 (Fig 5b). Wild type mice were able to
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Fig 5.

C57BL/6 mice are tolerized to HuD. (a) HuD-/- , HuD+/+ and

WT C56BL/6 mice were immunized with AdVHuD + PTx. 13 days after
immunization, CD8 T cells were isolated from the spleens and plated in
an IFNg ELISPOT assay (2 x 105/well) with peptide-pulsed EL4 cells (5 x
105/well).

(b) half of the spleens from mice immunized in (a) were

stimulated in vitro with p321. After 7 days, CD8 T cells were isolate from
stimulation cultures and plated in an IFNg ELISPOT assay (104/well)
with peptide pulsed EL4 cells (5 x 104/well).

86

generate

activated

HuDp321-specific

CD8

T

cells

after

in

vitro

stimulation. Taken together, these results show that HuD-specific CD8 T
cells are subject to tolerance induction in vivo.

HuC-deficient mice remain tolerized to HuD
Tolerance can be achieved by the generation of CD4 regulatory T cells. If
regulatory T cells are responsible for tolerance induction to HuD, these
cells may be specific for CD4 T cell epitopes shared between HuD and
other family members.

In order to determine if tolerance to HuD was

dependent on the presence of HuD protein specifically or induced by
other Hu family members, we took advantage of the HuC knockout
mouse. The HuD and HuC proteins are closely related, however the HuC
homolog of HuDp321 differs by a single amino acid (Fig 3a). In fact, the
amino acid sequence of p321 is not found in any other Hu family
member.

If tolerance depends on other T cell epitopes aside from

HuDp321, then deletion of the HuC gene could result in a loss of
tolerance to HuD. In order to investigate tolerance induction by other Hu
family members, we immunized mice deficient for HuC with adenovirusHuD and asked if HuDp321-specific CD8 T cells were activated in vivo
(Fig 6). HuC-deficient animals showed no response to HuDp321 directly
ex vivo (Fig 6a).

After stimulating splenocytes in vitro with p321,

however, HuDp321-specific CD8 T cells were able to secrete IFNγ,
ensuring an effective immunization (Fig 6b). We can conclude that
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Fig 6.

HuC-/- mice remain tolerized to HuD. (a) HuC-/- and HuC+/-

mice were immunized with AdVHuD + PTx. 13 days after immunization,
CD8 T cells were isolated from the spleens and plated in an IFNg
ELISPOT assay (2 x 105/well) with peptide-pulsed EL4 cells (5 x
104/well). (b) splenocytes from mice immunized in (a) were stimulated in
vitro with p321. After 7 days, CD8 T cells were isolate from stimulation
cultures and plated in an IFNg ELISPOT assay (104/well) with peptide
pulsed EL4 cells (5 x 104/well).
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tolerization of HuDp321-specific CD8 T cells does not require HuC, but is
dependent on HuD specifically.

CD4 depletion does not overcome tolerance to HuD
Peripheral tolerance induction can depend on active suppression of
autoreactive clones by regulatory T cells.

In order to investigate the role

of regulatory T cells in maintaining tolerance to HuD, we depleted the
CD4 T cell population in vivo prior to adenovirus-HuD immunization (Fig
7).

CD4 depletion was achieved by injecting mice with anti-CD4

antibody, followed by immunization with adenovirus-HuD or adenovirusβ-gal. We measured activation of HuDp321-specific CD8 T cells in an
IFNγ ELISPOT assay.

To assess the efficacy of our depletion regiment,

splenocytes were analyzed for the presence of CD4 and CD8 T cells.
There were no CD4 T cells remaining in the depleted mice two weeks
after immunization with adenovirus-HuD (Fig 7). The absence of CD4 T
cells did not overcome tolerance to HuD, as we saw no IFNγ secretion
directly ex vivo in response to p321. It is important to note that CD4
depletion does not specifically target regulatory T cells but instead
eliminates the entire CD4 T cell population. The absence of CD4 T cells
did not effect T cell priming by immunization with recombinant
adenovirus, since CD4-depleted mice immunized with adenovirus-β-gal
were able to generate activated β-gal-specific CD8 T cells (Fig 7). Still, β-
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Fig. 7.
C57BL/6

CD4 depletion does not overcome tolerance to HuD.
mice

were

injected

with

anti-CD4

antibody

GK1.5

(500ug/mouse) i.p. on days -7 and -4. On day 0, mice were immunized
with AdVHuD or AdVBgal + PTx (2 mice per group).

13 days after

immunization, CD8 T cells were isolated from the spleens and plated in
an IFNg ELISPOT assay (2 x 105/well) with peptide-pulsed DC (7 x
103/well).

Splenocytes from each mouse were analyzed on day 13 by

FACs to ensure CD4 depletion.

Splenocytes from control mice

immunized with AdVHuD or AdVBgal + PTx were analyzed by FACs (No
depletion).
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gal is not an autoantigen like HuD, so that CD8 T cell priming to HuD
may require CD4 T cells whereas CD8 T cell priming to β-gal does not.

AIRE does not regulate tolerance to HuD
In order to explore the role of AIRE in mediating tolerance to HuD, we
immunized AIRE-deficient mice with adenovirus-HuD and assessed
HuDp321-specific CD8 T cell activation directly ex vivo.

We reasoned

that if AIRE were to regulate tolerance to HuD, then AIRE-deficient
animals should mount an immune response similar to that of HuDdeficient mice.

After immunization of an AIRE-deficient mouse and its

wild-type littermate with adenovirus-HuD, we saw no response directly
ex vivo to HuDp321 in either animal (Fig8a). A portion of the spleen from
each animal was stimulated in vitro with p321 in order to ensure that our
immunization was successful and that AIRE mice did not have gross
immunologic abnormalities that prevented HuD CD8 T cell priming.
After in vitro stimulation, both the AIRE-deficient mouse and its wild type
littermate generated a typical HuDp321-specific CD8 T cell response (Fig
8b).

We can conclude that AIRE does not influence tolerance induction

to HuD.

Summary
HuDp321-specific CD8 T cells were not detectable by IFNγ secretion
directly ex vivo after immunization with adenovirus-HuD but could be
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Fig 8.

AIRE does not regulate tolerance to HuD. (a) AIRE-/- and

AIRE+/+ mice were immunized with AdVHuD + PTx.

13 days after

immunization, CD8 T cells were isolated from the spleens and plated in
an IFNg ELISPOT assay (2 x 105/well) with peptide-pulsed EL4 cells (5 x
104/well). (b) splenocytes from mice immunized in (a) were stimulated in
vitro with p321. After 7 days, CD8 T cells were isolate from stimulation
cultures and plated in an IFNg ELISPOT assay (104/well) with peptide
pulsed EL4 cells (5 x 104/well).
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expanded and activated in vitro upon stimulation with peptide. Tolerance
to HuD is normally maintained, since immunization of HuD-deficient
mice with adenovirus-HuD generated a robust ex vivo response from
HuDp321-specific CD8 T cells that did not require in vitro stimulation.
Aggressive immunization of wild type mice with peptide 321 emulsified in
Titermax adjuvant elicited a strong ex vivo IFNγ response from HuDp321specific CD8 T cells, demonstrating that these cells exist in the repertoire
and are not subject to central tolerance induction.

In comparison,

HuAp268-specific CD8 T cells were not detectable after immunization
with Titermax-peptide, which is indicative of thymic deletion.

HuAp268

binds with higher affinity to Db MHC I compared to HuDp321, and amino
acid residues flanking the two peptides are conserved, suggesting that
both are naturally processed and presented in a similar manner.

There

is a single amino acid difference between the two peptides at the fourth
residue, which is thought to affect the interaction with the T cell
receptor.

Central deletion of HuAp268 reactive T cells is critical to

prevent peripheral autoimmune disease, given the ubiquitous expression
pattern of the protein.

CD8 T cells specific for a neuronal antigen like

HuD escape central tolerance induction and are instead subjected to
regulation in the periphery.

The fact that patients with the Hu

syndrome never succumb to peripheral autoimmunity suggests that the
HuD-specific immune response is unable to cross-react with HuA. We
have formally shown that HuDp321-specific CD8 T cells do not recognize
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processed and presented HuA.

Thus, the immune response to HuD is

neuron-specific, and tolerance to this neuronal antigen is critical to
protecting the nervous system from autoimmune degeneration.
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CHAPTER V. HUD-SPECIFIC CD8 T CELLS IN THE CNS

Introduction
Patients with the Hu syndrome develop neurologic symptoms that affect
discrete areas of the nervous system including the dorsal root ganglia,
limbic system, cerebellum, brainstem, motor or autonomic nervous
system.

Most patients go on to develop multifocal neuronal

degeneration and die from neuronal causes, on average, seven months
after diagnosis.

The disease is characterized by neuronal loss and

inflammatory infiltrates of the nervous system.

The presence of high

titer antibodies to Hu serves as a diagnostic tool, however the role of
antibodies in disease pathogenesis remains unclear.

Given the

intracellular nature of HuD, it seems likely that CD8 T cells play an
important role in disease pathogenesis.

We have identified the

immunodominant CD8 T cell epitope of HuD in order to model CD8 T cell
mediated neuronal degeneration in mice.

Upon adoptive transfer of

HuD-specific CD8 T cells into recipient mice, we sought to assess the
ability of these cells to traffic to the CNS.

In addition, we measured

recruitment of peripheral APCs and upregulation of MHC I and MHC II
molecules on resident microglia, as these are hallmarks of inflammatory
CNS diseases.

In order to assess neuronal loss, we sent tissue sections

from the CNS to an independent pathologist for review.
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Results
Adoptive transfer of HuD-specific CD8 T cells
In order to study the ability of HuD-specific CD8 T cells to traffic to the
central nervous system and target HuD expressing neurons, we
developed a system that relied on the adoptive transfer of labeled CD8 T
cells into a host animal (Fig 1a).

Based on the results of our in vivo CTL

experiments, we opted to transfer stimulated CD8 T cells along with
syngeneic dendritic cells pulsed with cognate peptide. Host animals also
received pertussis toxin and exogenous IL-2.

IL-2 was used for its

ability to augment the function of transferred T cells.

In a published

model of tumor regression mediated by adoptive transfer of self-reactive
CD8 T cells, it was shown that IL-2 increases the number and function of
self-specific T cells (Overwijk, Theoret et al. 2003).

Given these results,

we reasoned that IL-2 could support the expansion and cytolytic ability
of transferred HuD-specific CD8 T cells.

In order to distinguish

transferred CD8 T cells from the host repertoire, we transferred
stimulated CD8 T cells derived from the congenic Thy1.1 mouse strain.
Thy1.1 is an isoform of the Thy1 glycoprotein found exclusively on T
cells; wild-type C56BL/6 mice carry the Thy1.2 isoform, which is easily
differentiated from Thy1.1.
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HuDp321-specific CD8 T cells can traffic to the central nervous system
In our initial adoptive transfer experiment we used Rag-/- mice as the
recipients of CD8 T cells.

Rag-/- mice received β-galp96-specific or

HuDp321-specific CD8 T cells together with cognate peptide-pulsed DCs,
pertussis toxin and IL-2.

To assess the purity of transferred CD8 T

cells, we stained a representative sample of cells for Thy1.1 and CD8 T
cell markers (Fig 1b). Roughly 90% of the transferred cells were positive
for Thy1.1 and CD8.

To assess CD8 T cell trafficking to the nervous

system, we sacrificed recipients one month after transfer and isolated
cells from brain (Fig 2).

For comparison, we measured CD8 T cell

trafficking to the spleen.

Both Thy1.1 β-gal-specific CD8 T cells and

Thy1.1 HuD-specific CD8 T cells were found in the spleens of recipients
one month post-transfer, ensuring that our adoptive transfer strategy
allowed for the survival and persistence of transferred T cells. Thy1.1 T
cells in the spleens expressed high levels of the CD8 co-receptor, as
expected.

When we examined the brains of recipient animals, we

detected Thy1.1 transferred T cells, indicating that these cells could
indeed traffic to the central nervous system. Trafficking to the brain was
not dependent on the presence of antigen behind the blood brain barrier,
as both β-gal-specific CD8 T cells and HuD-specific CD8 T cells were
found in the CNS.

Thy1.1 cells in the brain had down-regulated the

CD8 co-receptor (Fig 2).

Down-regulation of CD8 was not antigen-

dependent but perhaps a result of the brain’s cytokine milieu. The CD8
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Fig 1. Adoptive transfer of HuDp321-specific CD8 T cells. (a) for
adoptive transfer experiments, C57BL/6 mice (WT or Rag-/-) received 5 x
106 in vitro stimulated Thy1.1 HuDp321-specific or Bgalp96-specific CD8
T cells (i.v.) with 2 x 106 cognate peptide-pulsed DC (i.v), PTx, and IL-2.
(b) to assess the purity of transferred CD8 T cells, transferred cells were
stained for Thy1.1 and CD8 T cell markers.
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Fig 2.

Transferred CD8 T cells traffic to the CNS.

Rag-/- mice

received an adoptive transfer of HuD-specific (red mouse) or Bgal-specific
(blue mouse) Thy1.1 CD8 T cells as described in Fig 1a.

One month

later, cells from the spleens and brains of perfused recipients were
stained for Thy1.1 and CD8 T cells markers.
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co-receptor is an important component of the T cell receptor signaling
pathway that affects proliferation and activation of CD8 T cells.

Down-

regulation of the CD8 molecule in the CNS may be a means of
suppressing T cells and thereby inhibiting potentially damaging immune
responses.

HuDp321-specific CD8 T cells from the central nervous are capable of
secreting IFNγ in vitro
Given that transferred CD8 T cells in the brain down-regulate the CD8
co-receptor, we asked if these cells were permanently suppressed as a
result of trafficking to the CNS.

IFNγ secretion was used as an

indication of T cell activation. CD8 T cells isolated from the brain were
assessed for the ability to secrete IFNγ in response to cognate peptide in
an ELISPOT assay (Fig 3). As a positive control, we isolated cells from
the spleens of recipients and measured IFNγ secretion.

Both β-gal-

specific CD8 T cells and HuD-specific CD8 T cells isolated from the
spleen were capable of producing IFNγ in response to cognate peptide.
Cells from the brain were also able to secrete IFNγ, demonstrating that
suppression in CNS was not permanent but easily reversed ex vivo.
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Fig 3.

Transferred CD8 T cells in the CNS are not anergic.

WT

C57BL/6 mice received an adoptive transfer of Thy1.1 HuD-specific (red
mouse) or Bgal-specific (blue mouse) CD8 T cells as described in Fig 1a.
One month later, bulk cells from the spleens and brains of perfused
recipients were plated in an IFNg ELISPOT assay with 1ug cognate or
irrelevant peptide. Cells were also stained for Thy1.1.
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HuDp321-specific CD8 T cells in the central nervous system are not
sufficient for the induction of inflammation and neurologic degeneration
From our previous results we can conclude that CD8 T cells specific for
HuD are able to traffic to the CNS after adoptive transfer but are unable
to cause gross neurologic degeneration despite the presence of cognate
antigen in the brain.

Clearly, there is an additional requirement apart

from HuD-specific CD8 T cell entry into the brain that is required for
autoimmune destruction of HuD expressing neurons.

In EAE, which is

characterized by CD4 T cell mediated autoimmune destruction of myelin
in the CNS, T cell infiltration is accompanied by inflammation behind the
blood brain barrier.

Hallmarks of this inflammatory response are

recruitment of peripheral APCs to the brain and up-regulation of MHC I
and MHC II molecules on resident microglia.

Because there were no

apparent signs of neuronal loss in our adoptive transfer recipients, we
asked if this was do to a lack of inflammation in the CNS. As a measure
of inflammation in the CNS, we assessed recruitment of peripheral APCs
to the brain in recipient mice. Both microglia and peripheral APCs are
CD11b+ myeloid-derived cells that are distinguished by their levels of
CD45 expression.

Microglia are a defined CD11b+CD45intermediate

population whereas peripheral macrophages/DC are CD11b+CD45high
cells.

As a positive control for CNS inflammation, we analyzed APC

recruitment to the CNS in a symptomatic EAE animal (Fig 4). Here, we
saw a significant number of peripheral APCs in the brain, in addition to

102

Fig 4. Peripheral APC are recruited to the CNS in EAE. C57BL/6
mice were immunized with MOG35-55 in CFA + PTx to induce EAE.

Brain

cells from an asymptomatic mouse (score 0) and a symptomatic mouse
(score 2.5) were stained for CD45 and CD11b.
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resident microglia. In comparison, an immunized asymptomatic mouse
with no visible signs of EAE did not exhibit recruitment of antigen
presenting cells from the periphery (Fig 4).

When we examined the

brains of adoptive transfer recipients, we saw little recruitment of
macrophages or DCs from the periphery (Fig 5).

These results

demonstrate a lack of inflammation in the CNS of our adoptive transfer
mice, despite the presence of HuD-specific CD8 T cells and cognate
antigen behind the blood-brain barrier.

Trafficking of activated T cells

to the brain is not antigen-dependent, as activated T cells are readily
allowed access to this compartment, presumably as a means of
monitoring the CNS for infection. Initiation of an inflammatory response
behind the blood brain barrier requires the recruitment of peripheral
antigen presenting cells and up-regulation of antigen processing and
presentation machinery.

HuDp321-specific CD8 T cells in the inflamed CNS are not sufficient for the
induction of neuronal degeneration
HuD-specific CD8 T cells were unable to induce inflammation and
neuronal

degeneration.

In

order

to

generate

an

inflammatory

environment in the CNS, we induced EAE in recipient animals before the
adoptive transfer of HuD-specific CD8 T cells (Fig 6).

C57BL/6 mice

were immunized with MOG peptide to initiate EAE. Prior to the onset of
clinical disease, HuD- or β-gal-specific CD8 T cells were adoptively
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Fig 5.

Peripheral APC are not recruited to the CNS after adoptive

transfer of HuD-specific CD8 T cells. Rag-/- mice received an adoptive
transfer of Thy1.1 HuD-specific (red mice) or Bgal-specific (blue mice)
CD8 T cells (as in Fig 1a). One month later, cells from the brains of
perfused recipients were stained for CD45 and CD11b.
indicate percentages of CNS infiltrating APCs.
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Numbers

Fig 6. Adoptive transfer of HuDp321-specific CD8 T cells into EAE
mice. C57BL/6 mice were immunized with MOG35-55 in CFA + PTx to
induce EAE. 6 days later, mice received 5 x 106 in vitro stimulated
Thy1.1 HuDp321-specific or Bgalp96-specific CD8 T cells (i.v.) with 2 x
106 cognate peptide-pulsed DC (i.v), PTx, and IL-2.
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transferred into MOG-immunized recipients.

Mice exhibited clinical

symptoms of demyelination, with no exacerbation or mitigation of disease
by transferred HuD-specific T cells. When brain and spinal cord sections
were examined by histology, there were visible signs of inflammation and
infiltration by immune cells, however no neuronal damage was observed
(Fig 7).

Brain cells from recipients exhibited marked up-regulation of

MHC I and MHC II molecules on resident microglia and infiltrating
peripheral APCs (Fig 8).

Induction of EAE was effective at generating

inflammation in the CNS, however this was not sufficient for the
initiation of neuronal degeneration by HuD-specific CD8 T cells.

Summary
Upon adoptive transfer, HuD-specific CD8 T cells were able to traffic to
the CNS. Recruitment to the brain was not antigen-dependent, as both
HuD- and βgal-specific CD8 T cells were present behind the blood brain
barrier.

Transferred T cells isolated from spleens of recipient animals

were positive for both Thy1.1 and CD8 markers.

When lymphocytes

from the brain were analyzed, Thy1.1 transferred T cells were lacking in
expression of the CD8 coreceptor.

Downregulation of the CD8

coreceptor was possibly due to the immunosuppressive environment in
the CNS, which is designed to limit the generation of inflammatory
immune responses.

Any suppression of transferred CD8 T cells within

the CNS was reversed after removal of these cells from the brain followed
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Fig 7. Adoptive transfer of HuDp321-specific CD8 T cells into EAE
mice does not result in neuronal degeneration. EAE was induced in
C57BL/6 mice before adoptive transfer of Thy1.1 HuD-specific or Bgalspecific CD8 T cells (as described in Fig 6). Mice were sacrificed when
disease reached a clinical score of 2 (partial hind limb paralysis) and
perfused with PBS followed by paraformaldehyde. Brain and spinal cord
sections were fixed in formalin. Fixed tissues were sent to Charles River
for analysis.

(a) H & E staining on a representative mouse that received

HuD-specific T cells. (b) H & E staining on a representative mouse that
received Bgal-specific T cells.
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Fig 8. MHC I and II are upregulated in the CNS during EAE.

EAE

was induced in C57BL/6 mice before adoptive transfer of Thy1.1 HuDspecific or Bgal-specific CD8 T cells (as described in Fig 6).

Brain cells

from two representative mice, both with a clinical score of 2.5, were
stained for MHCI and MHC II expression. Histograms show MHC I and
MHC II expression on microglia cells (CD11b+CD45int) and peripheral
APC (CD11b+CD45hi).

In red is a mouse that received HuD-specific T

cells, in blue is a mouse that received Bgal-specific T cells.
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by stimulation with cognate peptide. Both HuD- and βgal-specific CD8 T
cells isolated from the CNS were able to secrete IFNγ in response to
cognate peptide in an ELISPOT assay.

Although HuD-specific CD8 T

cells were able to traffic to the brain when transferred into Rag-/recipients, we saw no signs of inflammation or neuronal loss in the CNS,
despite the presence of HuD antigen and the absence of regulatory T cells
in these hosts. Restimulation of infiltrating lymphocytes is an important
step in the generation of CNS inflammation, and depends on peripheral
APC recruitment and upregulation of MHC molecules on resident
microglia.

The inability of HuD-specific CD8 T cells to induce disease

was likely due to a lack of restimulation behind the blood brain barrier.
We saw no recruitment of APCs to the CNS, and no upregulation of MHC
molecules on microglia in our adoptive transfer recipients.

In order to

artificially create an inflammatory environment for transferred HuDspecific T cells, we generated EAE in recipient mice.

These mice

displayed characteristic clinical signs of demyelinating disease, and
exhibited high expression of MHC I and MHC II molecules on both
microglia and peripheral APCs in the CNS.

Examination of CNS tissue

revealed a lack of neuronal degeneration but obvious areas of infiltration,
and mice did not appear visibly affected by the transfer to activated HuDspecific CD8 T cells.
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CHAPTER VI. IDENTIFICATION OF HUMAN HLA CD8 T CELL
EPITOPES OF HUD

Introduction
We sought to identify clinically relevant human HuD epitopes in order to
better understand and diagnose anti-Hu syndrome.

Our immediate goal

was to use the results of this comprehensive peptide screen to design
HuD-specific tetramers that would allow us to visualize and characterize
HuD-specific CD8 T cells in the blood and cerebrospinal fluid of patients.
Using a novel approach to epitope discovery developed by Beckman
Coulter, we screened the entire HuD peptide library over 8 human HLA
MHC I alleles. Each HuD peptide was evaluated based on its affinity and
off-rate for individual MHC alleles.

Based on the results of this screen,

peptides were given a numerical score and ranked, with higher scores
signifying more likely CD8 T cell epitopes.

Data for all 8 human HLA

MHC alleles were acquired. We chose to evaluate peptides restricted to
the HLA A2.1 and HLA A3.1 alleles, since these are two of the most
prevalent MHC alleles in the western population.

Tetramers were

designed for each potential epitope, which were used to analyze patient
blood for the presence of HuD-specific CD8 T cells.

This provided

irrefutable evidence of HuD-specific CD8 T in the blood of patients with
the Hu syndrome.
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Results
A comprehensive screen to identify human HuD epitopes
To identify human epitopes of HuD, we generated a complete HuD
peptide library consisting of 386 overlapping nonamers, including
peptides derived from all known splice variants of the protein.

Each

peptide was screened for its ability to bind to recombinant HLA MHC I
molecules. We screened the entire HuD peptide library over 8 different
HLA alleles, including HLA A2.1 and HLA A3.1. Together, HLA A2.1 and
HLA A3.1 are carried by roughly 40% of the Caucasian population,
making them two of the most common MHC I alleles. For this reason,
our studies focused on epitopes presented by these specific MHC
molecules, although future work will extend to all 8 alleles examined in
the screen.

Peptides were ranked according to a final iScore, which was

generated based on binding, affinity and off-rate measurements.

We

identified 39 HLA A2.1-restricted peptides with significant iScores. To
narrow down this list of potential HLA A2.1 HuD epitopes, we reasoned
that pathologically relevant HuD-specific CD8 T cells should recognize
peptides that are not shared between HuD and its closely related family
member HuA. As previously discussed, HuA is a ubiquitously expressed
protein found throughout the body.

Moreover, patients with the Hu

syndrome generate an immune response that targets the nervous system
exclusively, leaving peripheral tissues unaffected. This lack of peripheral
autoimmunity suggests that relevant disease epitopes are not common to
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HuA.

Of the 39 HLA A2.1-restricted peptides, 20 were different in

sequence from HuA and therefore chosen for further evaluation.

HuDp157 is a naturally processed A2.1 epitope
In order to determine which of these 20 potential HuD HLA A2.1restricted peptides are naturally processed and presented epitopes, we
took advantage of the AAD transgenic mouse that expresses human HLA
A2.1 molecules.

Because HuD is highly conserved, with only two amino

acid differences between the mouse and human proteins, we were able to
immunize A2.1 transgenic mice with adenovirus-HuD to assess natural
processing and presentation without fear of priming responses to neoepitopes.

AAD mice were immunized with adenovirus-HuD in

combination with pertussis toxin to allow for natural processing and
presentation of HuD epitopes onto HLA A2.1 molecules and subsequent
CD8 T cell priming in vivo.

CD8 T cells from immunized mice were

stimulated in vitro with each of the 20 peptides and assessed for their
ability to secrete IFNγ in response to cognate peptide in an ELISPOT
assay (Fig 1). Of the 20 potential epitopes, 11 were able to elicit IFNγ
secretion from CD8 T cells in an antigen-dependent manner.

It seemed

unlikely that all 11 peptides represented true HuD epitopes, and we
therefore chose to assess natural processing and presentation in a more
stringent assay. We re-screened CD8 T cells from immunized mice in an
ELISPOT assay using syngeneic stimulators infected with adenovirus-
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Fig. 1.

Screening HLA A2.1 restricted HuD peptides in AAD mice.

Spleen cells from AAD mice immunized with AdVHuD + PTx were
stimulated in vitro with the peptides indicated on the x-axis. After ten
days of stimulation, purified CD8 T cells were plated in an IFNγ ELISPOT
with EL4-A2.1 cells pulsed with relevant or irrelevant peptide.

114

HuD (Fig 2). In this way, HuD epitopes were naturally processed and
presented onto HLA A2.1 molecules both for priming in vivo and for
antigen-specific IFNγ secretion in vitro.

Because AAD mice retain

expression of mouse H-2b MHC I molecules, we used three sets of
syngeneic stimulators in the ELISPOT assay to ensure that IFNγ
secretion was in response to peptides presented on HLA A2.1 rather than
mouse Db or Kb molecules.

Syngeneic stimulators consisted of kidney

cells from AAD, HHD, or C57BL/6 mice.

Again, AAD mice express both

mouse MHC I molecules as well as human A2.1, whereas HHD mice are
deficient for mouse MHC I and express only human A2.1. C57BL/6 mice
are wild type H-2b mice that express Kb and Db molecules.

Kidney cells

derived from each of these three strains were infected with either
adenovirus-HuD or, as a control, adenovirus-GFP.

A true HLA A2.1-

restricted epitope of HuD should elicit a response from HuD-specific CD8
T cells only when presented by either AAD or HHD kidney cells infected
with adenovirus-HuD. IFNγ secretion should not be seen in response to
C57BL/6 kidney cells infected with adenovirus-HuD, as this would imply
presentation by mouse H-2b MHC I.

Of the 11 peptides that screened

positive in the initial ELISPOT assay, only two elicited IFNγ secretion in
response to AAD and HHD kidney cells infected with adenovirus-HuD
(Fig. 2).

Peptides 157 and 287 appeared to be true A2.1-restricted HuD

epitopes, and we therefore sought to generate tetramers for both
peptides. Due to technical difficulties, p287-specific tetramers were
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Fig. 2.

HuDp157 is a naturally processed A2.1-restricted epitope.

CD8 T cells purified from spleen stimulation cultures were tested for
their ability to recognize whole HuD protein processed and presented by
primary kidney cells infected with AdVHuD (or AdVGFP as a negative
control). CD8 T cells specific for HuDp157, HuDp287, or HuDp315 were
plated in an IFNg ELISPOT with infected kidney cells from AAD mice (top
panel), HHD mice (middle panel), or wild type mice (bottom panel).
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impossible to create and after several rounds of discussion with iTopia
consultants from Beckman Coulter, we chose to discount p287 as a real
HuD epitope.

HuDp157 specific T cells are present in the blood of Hu patients
We designed HLA A2.1-restricted tetramers specific for HuDp157 in order
to screen the blood of patients with the Hu syndrome for the presence of
HuDp157-specific CD8 T cells.

After a single round of in vitro

stimulation with p157, we detected a population of HuDp157-specific
CD8 T cells from an HLA A2.1+ Hu patient but not from HLA A2.1+
normal donors (Fig 3). Normal donors exhibited an expanded population
of CD8 T cells specific for common viral epitopes of influenza or CMV (Fig
3). This was the first direct proof of HuD-specific T cells in the blood of
an Hu patient. Taken together, these results support the hypothesis that
CD8 T cells play an important pathological role in autoimmune
neurologic degeneration.

HuDp157-specific CD8 T cells from patients are functional cytotoxic T cells
Our model of disease pathogenesis depends on the destruction of HuDexpressing tumor cells and neurons by effector HuD-specific CD8 T cells.
To show that CD8 T cells isolated from Hu patients are capable of lysing
HuDp157-expressing targets, we performed a CTL assay with tetramersorted HuDp157-specific T cells. We chose to tetramer-sort T cells from
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Fig 3.

HuDp157-specific T cells are present in Hu patient blood.

Peripheral blood T cells from one Hu patient and four normal donors
were expanded in vitro with HuDp157 and stained with HuDp157-specific
or irrelevant peptide-specific (negative) tetramer.

As a control,

peripheral blood T cells were expanded with M1 or CMV peptide and
stained with relevant tetramer.
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Fig. 3
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patients because previous attempts to assess the function of HuDspecific T cells using bulk T cell cultures were unsuccessful.

We

reasoned that the frequency of HuD-specific T cells isolated from patient
blood was too low for detection in our assays.

To overcome this

limitation, we stimulated patient T cells in vitro with p157 prior to sorting
tetramer-positive CD8 T cells from bulk T cell stimulation cultures.
Tetramer-sorted HuDp157-specific CD8 T cells from two individual Hu
patients were used in CTL assays with cognate or irrelevant peptidepulsed targets.

HuDp157-specific CD8 T cells from both patients were

able to lyse target cells in an antigen-dependent manner (Fig 4).
results

strengthen

our

model

of

CD8

T

cell

mediated

pathogenesis, and mimic the results from our mouse system.

These
disease
Both

human and mouse HuD-specific CD8 T cells are able to act as cytotoxic
T cells, but require isolation and in vitro stimulation in order to expand
and acquire effector function.

HLA A3.1 restricted HuD-specific CD8 T cells from patients are functional
cytotoxic T cells
To identify clinically relevant HLA A3.1 restricted epitopes of HuD, we
used the five top-scoring peptides from the iTopia screen in patient
experiments. Because there were fewer candidate peptides for A3.1 than
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for A2.1, we chose to move directly to A3.1+ patient assays. T cells from
four A3.1+ Hu patients were used to screen the A3.1-restricted candidate
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Fig. 4.

HuDp157-specific T cells from patients are functional

cytotoxic T cells. (a) HuDp157 and influenza M1 tetramer+ T cells from
an Hu patient were expanded in vitro with peptide, followed by FACS
sorting of the tetramer+ population.

Tetramer+ cells were allowed to

recover with irradiated, peptide-pulsed, autologous PBMC and IL-2.
After recovery, T cell lysis was measured in a CTL assay with peptidepulsed T2 cells.

(b) lytic functions of HuDp157 and influenza M1

tetramer+ T cells from a second Hu patient were measured as in (a).
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peptides.

CD8 T cells were cultured for 8 days with autologous peptide-

pulsed DCs to expand antigen specific T cells before their use in tetramer
and CTL assays.

Of the five A3.1 candidate peptides, HuDp133 was the

only peptide capable of expanding CD8 T cells from patient blood (Fig 5).
One out of four Hu patients exhibited expansion of HuDp133 specific T
cells (Fig 5).

In comparison, none of the neurologically normal A3.1+

control patients had an expanded HuDp133 population, but all
demonstrated expansion of influenza specific T cells.

The lack of

HuDp133-specific CD8 T cells in three of the four A3.1+ Hu patients is
not surprising, considering that these patients have other HLA MHC I
alleles in addition to A3.1, and may generate HuD-specific responses to
epitopes restricted to these other alleles.

Expanded HuDp133-specific

CD8 T cells were assessed for the ability to lyse target cells expressing
cognate peptide (Fig. 6). Bulk T cells were stimulated in vitro with each of
the five A3.1-restricted HuD peptides before use in a CTL assay.
HuDp133-specific CD8 T cells were able to lyse targets in an antigendependent manner, demonstrating that HLA A3.1-restricted HuD-specific
T cells are functional effectors present in Hu patient blood.

Summary
CD8 T cells are the effector cells responsible for the destruction of
neurons and tumor cells in our model of the Hu syndrome. In order to
provide evidence in support of CD8 T cell mediated disease, we sought to
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Fig. 5. HuDp133 is an HLA A3.1-restricted epitope of HuD. Tetramer
staining of T cells from four different HLA A3.1 Hu patients and two
normal donors after expansion with five A3.1-restricted HuD peptides. T
cells were stained with tetramer specific for cognate A3.1 peptide or an
irrelevant tetramer. As a positive control, T cells were expanded with the
HLA A.3.1-restricted epitope of influenza nucleoprotein (NP) and stained
with NP-specific tetramer.
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Fig. 5
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Fig. 6.

HuDp133-specfic T cells are functional cytotoxic T cells.

T

cells from an A3.1+ Hu patient (Hu #1 in figure 5) were expanded in vitro
with five A3.1-restricted HuD peptides.

After expansion, cells were

stained with tetramer specific for cognate HuD peptide or irrelevant
peptide. Lytic function of the expanded T cells was measured in a CTL
assay with T2 cells pulsed with cognate HuD peptide or irrelevant
peptide.
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Fig. 6
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isolate and characterize HuD-specific CD8 T cells from patients.

This

required the identification of human CD8 T cell epitopes of the protein.
To this end, we performed a comprehensive screen of the entire HuD
peptide library over 8 human HLA alleles.

A list of potential epitopes

was generated from the screen, which lead to the discovery of two human
CD8 T cell epitopes of HuD.

Tetramers for these two epitopes were used

to examine the blood of Hu patients for the presence of HuD-specific CD8
T cells. We found an expanded population of HuD-specific CD8 T cells in
Hu patients but not in normal donors, indicating that these T cells play a
role in disease development. Tumor immunity and neurodegeneration in
the Hu syndrome require lysis of HuD-expressing cells by cytotoxic T
cells. We therefore assessed the lytic ability of HuD-specific CD8 T cells
isolated from the blood of Hu patients.

We found that A2.1- and A3.1-

restricted HuD-specific CD8 T cells from patients were efficient at
destroying target cells that expressed cognate HuD peptide.

This

provided clear evidence in support of our model of disease pathogenesis.
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CHAPTER VII. DISCUSSION

Development of neuronal autoimmunity in patients with SCLC appears
to depend on a loss of tolerance to the onconeural antigen HuD (Fig 1).
This destructive immune response against HuD-expressing neurons is
also able to mediate impressive tumor immunity. Tumor immunity and
neuronal autoimmunity are not always coupled, since a significant
number of SCLC patients mount an immune response to their cancer
that correlates with limited stage tumors and better prognoses in the
absence

of neurologic

disease

(Dalmau, Furneaux

et

al.

1990).

Understanding the mechanisms responsible for tolerance induction to
HuD, and how tolerance is broken in the presence of an HuD-expressing
tumor, are of great clinical significance with regard to designing better
therapies for SCLC.

In order to study tolerance to HuD in an animal model, we first identified
the immunodominant CD8 T cell epitope of the protein in C57BL/6 mice
through an exhaustive screen of the entire HuD peptide library.

We

found CD8 T cells specific for 7 peptides of the protein, and went on to
determine which of these represented naturally processed and presented
epitopes. This allowed for the identification of the immunodominant CD8
T cell epitope of HuD, p321.

HuDp321-specific CD8 T cells were

characterized in functional and phenotypic assays. We found that these
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Fig 1. Revised model of anti-Hu syndrome. HuD-specific T cells are
normally tolerized to the HuD protein. The presence of a small cell lung
cancer tumor that expresses HuD is able to break tolerance to the HuD
antigen in 15% of patients, resulting in an immune response against the
cancer. In 01% of patients, this immune response is also able to traffic
to the nervous system to mediate destruction of HuD expressing
neurons.
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cells, once activated in vitro, were high affinity T cells capable of lysing
targets in an antigen dependent manner. The inability to detect these
cells directly after immunization with recombinant adenovirus was the
first indication that HuD-specific CD8 T cells were subject to tolerance
induction.
toxin

in

Priming an effective immune response required pertussis
combination

stimulation with peptide.

with

adenovirus-HuD

followed

by

in

vitro

In vitro stimulation allowed for the expansion

of HuD-specific CD8 T cells, and served to eliminate any suppression felt
in vivo.

The role of pertussis toxin in our system was less clear.

It

obviously acted as an adjuvant, enhancing the immune response to HuD
in vivo in order to allow for further expansion in vitro.

Immunization

with adenovirus-HuD together with in vitro stimulation in the absence of
pertussis toxin failed to generate a detectable population of functional,
IFNγ-secreting HuD-specific CD8 T cells, indicating that pertussis toxin
served to quantitatively or qualitatively change the T cell response in vivo.
Still, pertussis toxin alone was not sufficient to generate detectable IFNγsecreting HuD-specific cells, since T cells isolated from mice immunized
with pertussis toxin and adenovirus-HuD did not secrete IFNγ in
response to antigen directly ex vivo, in the absence of in vitro stimulation.
The need for pertussis toxin together with in vitro stimulation for the
generation of HuD-specific CD8 T cells may be the result of low precursor
frequency in conjunction with peripheral tolerance induction.

Pertussis

toxin might relieve some of the suppression on HuD-specific T cells in
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vivo, but additional expansion by in vitro stimulation may be necessary
due to low precursor frequency.

Pertussis toxin has been shown to act as an adjuvant by inducing
maturation of dendritic cells, resulting in the expansion of effector T cells
and IFNγ production (Hou, Wu et al. 2003). It has also been implicated
in blocking the function of regulatory T cells, thereby promoting
productive immune responses (Chen, Winkler-Pickett et al. 2006).

The

means of inducing peripheral tolerance to HuD are still unclear. Anergy
induction

or

inhibition

by

regulatory

T

cells are

both possible

mechanisms of suppression of HuD-specific T cells, either of which
would be overcome by pertussis toxin.

Our preliminary experiments

have shown that depletion of CD4 T cells followed by adenovirus-HuD
immunization failed to generate a detectable HuD-specific response
directly ex vivo, implying that regulatory T cells are not responsible for
tolerance induction.

However, CD4 T cell depletion is not a specific

means of eliminating regulatory T cells, since the entire CD4 T cell
population is removed, which includes helper CD4 T cells that may be
required to assist in HuD-specific CD8 T cell priming.

Regulatory T cells

may be responsible, in part, for inhibiting HuD-specific immune
responses, given that HuD-specific CD8 T cells escape central tolerance
to circulate in the periphery with relatively high affinity for antigen.
Regulatory T cells could act to inhibit HuD-specific CD4 T cells, which
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would in turn prevent the activation of HuD-specific CD8 T cells.

A

coordinated response from both the CD4 and CD8 T cell arms of the
immune system is almost certainly required for the generation of HuDspecific autoimmunity, so that inhibition of HuD-specific CD4 T cells
would be an important means of inducing tolerance in the periphery.
Given that HuD is an intracellular antigen, cross-presentation of
exogenous protein is required for the initiation of HuD-specific CD8 T cell
responses. CD4 T cells are necessary for effective cross-presentation to
CD8 T cells, making their inhibition imperative to the prevention of HuDspecific CD8 T cell-mediated neurodegeneration (Albert, Jegathesan et al.
2001).

Anergy induction is a potential mechanism of HuD-specific CD8 T cell
suppression, which would depend on peripheral presentation of HuD to
circulating T cells.

Presentation of HuD could involve expression of the

protein by a non-neuronal cell type, for example a lymph node stromal
cell, which would result in anergy induction.

We have yet to find HuD

protein or RNA expression in any tissue outside of the nervous system,
however it may be expressed at extremely low levels, making detection
difficult. The transcription factor AIRE has been implicated in regulating
the expression of tissue-specific proteins by lymph node stromal cells for
the purpose of inducing tolerance, so we investigated its role in
controlling ectopic expression of HuD. However, HuD expression did not
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appear to be governed by AIRE. This does not rule out the possibility
that unidentified transcription factors exist in order to regulate
expression of HuD and other tissue-specific proteins for the purpose of
inducing tolerance.

In the absence of, or in addition to the ectopic

expression of HuD by a non-neuronal cell type, HuD-expressing neurons
may be cross-presented via DCs, resulting in cross-tolerization of HuDspecific CD8 T cells. However, neurons do not normally turn over, which
makes reliance on cross-presentation for tolerance induction potentially
dangerous.

It is possible that only pieces of neurons, in the form of

membrane-bound blebs, are taken up by DCs for cross-tolerization of
HuD-specific CD8 T cells.

We found it useful to compare tolerance induction to HuD versus its
related family member HuA. Given the ubiquitous expression of HuA, we
reasoned that tolerance to this protein should be stricter compared to
HuD.

Patients with the Hu syndrome develop autoimmunity that is

restricted to the nervous system but never directed against peripheral
tissues, suggesting that effector CD8 T cells responsible for disease
pathogenesis are unable to cross react with HuA.

Furthermore, patient

sera react with HuB, HuC and HuD but not with HuA. We hypothesized
that HuA-specific T cells should be centrally tolerized, since their
presence in circulation could lead to the generation of massive peripheral
autoimmunity.

If HuA is subject to central tolerance induction, there
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should not be T cells specific for any of the shared epitopes between HuD
and HuA in the repertoire.

We compared all 7 of the potential HuD

epitopes initially identified in our peptide screen for sequence homology
to their corresponding HuA epitopes. Of the 7 potential epitopes, 6 were
different in HuA, supporting the idea that HuA is centrally tolerized.

Of

these 7 potential epitopes, only one, HuDp321, proved to be naturally
processed and presented by the immune system.

We compared this

immunodominant HuD CD8 T cell epitope to its related epitope in HuA,
peptide 268. HuA p268 differs from HuD p321 at a single amino acid
position. The fourth residue is converted from an asparagine in HuD to a
threonine in HuA. This is a non-conserved amino acid difference, found
at a position that is known to interact with the T cell receptor but that
does not affect MHC binding affinity. In order to show that HuA p268
binds with similar affinity to MHC I compared to HuD p321, we
performed an MHC I stabilization assay. HuA peptide bound MHC I with
higher affinity than p321. When mice were immunized with either the
HuA peptide or HuD peptide emulsified in titermax adjuvant, there was a
strong response from HuDp321-specific CD8 T cells, however we did not
detect any HuAp268-specific T cells. The absence of HuA-specific T cells
strongly suggests that mice are centrally tolerized to the HuA protein.
Conversely, the existence of T cells specific for HuD in the repertoire
indicates that central tolerance does not apply to HuD.

Also, we have

demonstrated that AIRE, a transcription factor involved in the induction
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of central tolerance, does not regulate expression of HuD in mice.
Nevertheless, we cannot exclude the possibility that HuD is subject to
central tolerance induction via an AIRE-independent pathway, and that a
portion of HuD-specific T cell clones are able to escape thymic deletion,
resulting in a small precursor frequency in the periphery.

The initial immune response in patients with the Hu syndrome is
directed against HuD, since this is the only Hu family member expressed
in SCLC. Patients present with neurologic symptoms that affect discrete
areas of the nervous system but often go on to develop multifocal
neuronal degeneration. Although all Hu patients share the characteristic
anti-Hu antibody response that is correlated with tumor immunity and
neuronal autoimmunity, the regions of the nervous system affected vary
widely. The disease begins with an acute phase and can either plateau
to reach a state of chronic but not degenerating illness, or progressively
worsen from the time of diagnoses until death.

These differences among

patients reflect diverse pathways of disease progression that may be due
to genetic and environmental factors.

Every individual has a different

group of MHC molecules, referred to as the haplotype, which determines
the spectrum of peptides presented to the immune system.

MHC

haplotype can strongly influence disease susceptibility and immunity,
and almost certainly affects the onset and development of the Hu
syndrome.

The fact that most patients progress from neurologic
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symptoms targeted to discrete areas of the nervous system to multifocal
neuronal degeneration suggests that there may be epitope spread to
generate immune responses against other Hu family members during the
course of the disease.

The initial immune response to HuD in the

periphery via ectopic expression of this neuronal antigen by a SCLC
tumor might be expanded to include immune responses against other Hu
family members.

For instance, HuD-specific CD8 T cell-mediated

destruction of neurons that express both HuD and HuC could result in
the activation of HuC-specific T cells, which would then mediate
neuronal

degeneration

of

HuC

expressing

neurons,

resulting

in

multifocal disease.

Given the high sequence homology between the Hu proteins, there may
be a shared CD4 T cell epitope between Hu family members that
facilitates epitope spread.

The generation of effector CD8 T cell

responses to HuB or HuC would almost certainly depend on cognate CD4
T cell help, since cross presentation by an APC is required.

If the initial

immune response to HuD-expressing SCLC cells in the periphery results
in the activation of CD4 T cells that recognize a shared Hu epitope, these
same CD4 T cells would be primed to assist in the generation of an
immune response against other Hu family members.

In Hu patients, we

detect anti-Hu antibodies that recognize HuB, HuC, and HuD, indicating
that the B cell epitope of the protein is conserved among family members.
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Whether regulatory T cells, as opposed to helper CD4 T cells, recognize a
shared epitope is still unclear. We have shown that HuC expression is
not required for tolerization of HuD-specific CD8 T cells.

When HuC-

deficient animals were immunized with adenovirus-HuD, there was no
detectable HuD-specific response directly ex vivo, whereas HuD-deficient
mice showed a strong ex vivo response to HuDp321.

It would seem

efficient to generate regulatory T cells specific for a shared Hu epitope in
order to maintain tolerance to the Hu protein family, however our results
do not support this hypothesis.

What is clear is the requirement for

HuD expression for tolerization of HuD-specific CD8 T cells. Either HuD
expression serves to generate regulatory T cells specific for a CD4 epitope
that is unique to the protein, or is directly responsible for inducing
anergy in HuD-specific CD8 T cells. The CD8 T cell epitope of HuD is not
shared by other Hu family members, so that anergy induction would
necessarily require expression of HuD but not other Hu family members.

The presence of a SCLC tumor in the periphery that expresses HuD
appears to be the initial trigger for the generation of an anti-Hu immune
response.

This pocket of antigen, outside of the nervous system, is able

to break tolerance to HuD and elicit effective anti-tumor immunity.
steps required for the loss of tolerance are still unknown.

The

Certain

cytokines or growth factors produced by SCLCs may help to overcome
suppression and prime HuD-specific lymphocytes.
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Genetic differences

may also determine which SCLC patients are able to generate anti-Hu
antibodies and tumor immunity.

Given that 15% of SCLC patients

manufacture anti-Hu antibodies, the loss of tolerance is not a
particularly rare event.

What is rare is the generation of neuronal

autoimmunity, as only .01% of SCLC patients succumb to neurologic
disease.

There is obviously an additional, and more infrequent event

that distinguishes patients with autoimmune neurodegeneration from
those with low titer antibody and better tumor immunity in the absence
of neurologic disease.

Perhaps there are multiple mechanisms of

inducing tolerance to HuD in order to safeguard against neuronal
degeneration.

One form of tolerance may be overcome in neurologically

normal SCLC patients with anti-Hu antibodies, whereas most or all are
broken in anti-Hu patients, allowing for the development of neuronal
autoimmunity.

The fact that Hu patients generate high titer antibodies

to Hu, whereas neurologically normal patients produce low titer
antibodies, indicates a qualitative or quantitative difference in the
immune response in these two groups.

Since both sets of patients are

able to generate tumor immunity in the periphery, the distinguishing
mechanism or event that translates to neurologic disease would be likely
to occur in the nervous system. HuD is expressed in peripheral neurons
as well as in the CNS, so it is unclear if this distinguishing event
necessarily occurs behind the blood brain barrier.

It may instead

happen near peripheral neurons, and could require neuronal death or
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inflammation in order to prime a strong and lasting immune response to
HuD.

Patients with Hu antibodies generate a primary response to HuD

in the periphery that seems to depend on the ectopic expression of this
neuronal protein by a SCLC tumor.

The subsequent neuronal

autoimmunity in Hu patients should depend on the recognition of HuD
in the nervous system via cross presentation by a professional APC.

A

concurrent infection that generates inflammation would help to overcome
tolerance to the protein, resulting in a degenerative immune response
against HuD expressing neurons.

Patients with SCLCs that are able to generate natural tumor immunity in
the absence of neurologic disease offer invaluable insight into how the
body can recognize and destroy cancer.

In order to understand and

harness this natural tumor immunity for treatment of SCLC, it is
imperative that we understand the differences between neurologically
normal SCLC patients and patients with the Hu syndrome to ensure that
therapy does not cause autoimmune neurodegeneration. Understanding
the mechanisms behind autoimmune neurodegeneration requires the
creation of a mouse model of CNS disease mediated by HuD-specific T
cells.

To this end, we designed an adoptive transfer system to study T

cell mediated neuronal degeneration, using in vitro stimulated HuDp321specific CD8 T cells.

We found that upon adoptive transfer into

syngeneic recipients, HuDp321-specific CD8 T cells persisted up to one
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month post transfer and were able to traffic to the CNS.

However,

trafficking to the CNS was not antigen-dependent, as β-galactosidasespecific CD8 T cells were also found in the brain.

It has been shown in

other experimental systems that activated T cells routinely traffic to the
CNS in order to monitor this compartment for infection. Once inside the
CNS, both HuD-specific and βgal-specific CD8 T cells downregulated the
CD8 co-receptor. Downregulation of the CD8 co-receptor is arguably a
means of suppressing activated T cells within the brain in order to
protect against inflammation and tissue damage. HuD-specific and βgalspecific CD8 T cells in the CNS were not permanently suppressed,
however, since these cells could secrete IFNγ in response to peptide in an
ELISPOT assay.

Despite the presence of both activated HuD-specific

CD8 T cells and cognate antigen in the CNS, we saw no neurologic
disease in our experimental system.

The lack of disease appeared to be

due, in part, to a lack of inflammation behind the blood brain as there
was no recruitment of peripheral APCs or upregulation of MHC molecules
in the brain.

As a means of artificially creating CNS inflammation in

our adoptive transfer recipients, we induced EAE in host animals prior to
the transfer of HuD-specific CD8 T cells.

This resulted in clinical signs

of demyelination and characteristic recruitment of peripheral APCs
together with upregulation of MHC I and II expression on resident
microglia.

Nevertheless, recipient animals exhibited no signs of

neuronal degeneration by histology.
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The most obvious explanation for

the lack of disease is the absence of HuD-specific CD4 T cells in this
model.

Many models of brain disease involve recruitment of peripheral APCs to
the CNS. Reactivation of T cells via DCs behind the blood brain barrier is
an initiating step in the development of CNS inflammation (Becher,
Bechmann et al. 2006). Microglia are also activated during the
inflammatory response by upregulating expression of MHC molecules in
order to assist in the maintenance of inflammation.

Given that HuD is

an intracellular neuronal antigen, cross presentation by an APC is
presumably required for reactivation of T cells behind the blood brain
barrier in order to initiate an inflammatory response that ultimately
results in destruction of HuD-expressing neurons.

Cross-presentation

to CD8 T cells requires CD4 T cell help, so that the presence of an HuDspecific CD4 T cell in the brain is necessary for disease pathogenesis.
Even after the initial reactivation of T cells behind the blood brain
barrier, subsequent stages of disease depend on presentation of antigen
by microglia, which become active participants in the inflammatory
reaction. Exacerbation of disease by microglial antigen presentation to
HuD-specific CD8 T cells in the parenchyma would also require cross
presentation and CD4 T cell help.

The need for CD4 T cells in CNS

disease pathogenesis is indicated by the spontaneous development of
autoimmune-mediated

demyelination
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in

transgenic

mice

that

constitutively express the costimulatory molecule B7.2 on resident
microglia. In this model, microglia are permanently activated in the CNS,
which

leads

to

spontaneous

CD8

(Brisebois, Zehntner et al. 2006).

T

cell-mediated

demyelination

Constitutive expression of B7.2 on

microglia may eliminate the need for CD4 T cells if CD4 T cells are
normally important for the expression of costimulatory molecules on
microglia.

In this model, antigen-specific CD4 T cell recognition of

MHC-peptide complexes on resident microglia results in upregulation of
costimulatory molecule expression on microglia. Activated microglia are
then able to productively interact with CD8 T cells in the CNS and
maintain a state of inflammation behind the blood brain barrier.

In

transgenic mice that constitutively express B7.2 on microglia, the need
for CD4 T cells is eliminated since costimulatory molecule expression is
permanently induced.

Our model of autoimmune-mediated neurologic disease does not include
a CD4 T cell component. The CD4 T cell epitope of HuD is currently
unknown, and therefore the isolation and characterization of HuDspecific CD4 T cells is difficult.

In order to generate autoimmune-

mediated neurologic disease, it may be necessary to transfer HuDspecific CD8 T cells together with cognate CD4 T help.

In addition, the

production of a transgenic mouse expressing the HuDp321-specific T cell
receptor will be an invaluable reagent.
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It may be possible to bypass the

need for CD4 T cells by transferring a sufficient number of clonal HuDspecific CD8 T cells that have been stimulated in vitro. Transfer of CD8 T
cells 2 days after in vitro stimulation, when the cells are at their peak of
activation, may also help to eliminate the need for cognate CD4 T cell
help.

Ultimately, the generation of brain disease by HuD-specific T cells

that have been primed by a tumor expressing HuD in the periphery will
be the most informative model of autoimmune-mediated neuronal
degeneration.
tumor line.

To date, there is no naturally occurring HuD-expressing
It is possible to transfect a tumor line with the HuD gene,

however protein expression will most likely exceed physiological levels,
which may affect T cell priming in vivo.

In addition, transfection with

the HuD gene is problematic, since HuD is a biologically active protein
and most tumor cells will not tolerate its expression.

The ultimate goal of our studies on the Hu syndrome is to design better
diagnostic and therapeutic tools for the treatment of this aggressive form
of

autoimmune

neurodegeneration.

In

our

model

of

disease

pathogenesis, destruction of HuD expressing tumor cells and neurons
requires antigen-specific recognition and lysis by HuD-specific CD8 T
cells.

Isolation and characterization of HuD-specific CD8 T cells from

patients required the identification of human CD8 T cell epitopes of the
protein.

To this end, we performed a comprehensive screen of the entire

HuD peptide library over 8 human HLA alleles.
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A list of potential

epitopes was generated, which lead to the discovery of two human CD8 T
cell epitopes of HuD.

Tetramers for these two epitopes were used to

examine the blood of Hu patients for the presence of HuD-specific CD8 T
cells. We found an expanded population of HuD-specific CD8 T cells in
Hu patients but not in normal donors, indicating that these T cells play a
role in disease development.

Tumor immunity and neurodegeneration

require lysis of HuD-expressing cells.

We therefore assessed the lytic

ability of HuD-specific CD8 T cells isolated from the blood of Hu patients
in a CTL assay.

We found that HuD-specific CD8 T cells from patients

were efficient at destroying target cells that expressed cognate HuD
peptide. These results support our model of disease pathogenesis and
allow us to ask the important question of whether there are HuD-specific
CD8 T cells in patients with low titer antibody that are able to generate
tumor immunity without neurologic disease. If these patients are found
to harbor HuD-specific CD8 T cells, this would suggest that tolerance is
broken in both groups of patients with anti-Hu antibodies, regardless of
their neurologic state.

Breaking tolerance to HuD would allow for an

effective immune response to SCLC in the periphery and subsequent
tumor immunity. The development of neurologic disease in Hu patients
would require an additional step that translates the peripheral response
against HuD expressing tumor cells into an inflammatory autoimmune
response against HuD expressing neurons.
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SCLC is a disease that affects heavy smokers. It would also be extremely
informative to examine the blood of tumor-free long-term heavy smokers
for the presence of HuD-specific CD8 T cells.

If these cells were present

in this population, we could infer that HuD-specific CD8 T cells provided
effective protection from the growth of SCLC. Our goal is to harness the
natural tumor immunity generated in patients with anti-Hu antibodies
for the treatment of SCLC tumors, all of which express the HuD antigen.
If HuD-specific CD8 T cells are expanded in heavy smokers and in
neurologically normal patients with Hu antibodies, this would provide a
strong impetus for the generation of SCLC immunotherapy based on
HuD-specific CD8 T cells.
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